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ABSTRACT OF THE DISSERTATION

Are Antinuclear Antibodies and Rheumatoid Factor Positivity More Prevalent in
Apparently Healthy Smokers Compared to Ex-Smokers and Non Smokers?
by
Susan Nyanzi
Doctor of Public Health in Preventive Care
Loma Linda University, Loma Linda California, 2002
Dr. Jerry W. Lee, Chairman

Context: There is now consistent evidence from population and epidemiological
studies that cigarette smoking is an independent risk factor for Rheumatoid Arthritis
(RA), via Rheumatoid Factor (RF) production (Deighton, 1997; Saag, 1997; Silman,
1996; Uhlig, 1999; Wolfe, 2000). Antinuclear Antibodies (ANA) are another collection
of autoantibodies that are being associated with smoking and RA initiation. To our
knowledge, no studies have examined the effects of smoking on both ANA and RF
simultaneously in healthy subjects. Objectives: To determine whether cigarette smoking
has an effect on ANA and RF positivity in healthy blood donors. Design, Setting,
Participants: This was a cross-sectional, observational, retrospective study. 576
consenting volunteer blood donors recruited from the local blood banks gave additional
blood samples, answered the general blood bank questionnaire and our study
questionnaire. Data on demographics, smoking history and selected RA risk factors were
collected. Main Outcome Measures: ANA and RF positivity. Results: Moderate and
iii

light lifetime smoking was protective for ANA positivity relative to non-smoking and
heavy smoking (O/?=2.670, 95% C7= 1.322-5.391, /?=0.006). Simple contrasts suggested
this was due to moderate lifetime smoking being protective for ANA positivity compared
to non-smoking (<9/?=0.337, 95% C7=0.115-0.989, p=0.048) and heavy smoking
(<9/?=0.173, 95% C/=0.055-0.545,/?=0.003). No associations were found between
current smoking status and ANA or RF positivity. Nor was one found with past and
current second hand smoke. For never smokers there was an interaction of second hand
smoke exposure with age. Those not exposed to second hand smoke showed increasing
probability of ANA positivity with age. Those exposed to second hand smoke showed no
such increase (0/?=0.908, 95% C7=0.828-0.996, /?=0.042). Total years smoked for ex
smokers increased the likelihood of testing positive for ANA (0/?=l.O45, 95% C/+1.0071.084, /?=0.021). No associations were found between smoking status and ANA or RF
positivity. Conclusion: Immunological changes induced by smoking or nicotine may
help explain the observed biphasic effect found with ANA positivity. For ex-smokers,
smoke exposure may produce a permanent physiological change on the formation of
ANA complexes that is irreversible.
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CHAPTER 1
INTRODUCTION
A. Study Aim
The etiology of Rheumatoid Arthritis (RA) is multifactorial, involving both
genetic and environmental elements (Cohen, 1986; Copstead, 1995; Hess, 1988; Rubin,
1995; Zhang, 2001). The role of genetics is fairly minor and is primarily associated with
disease progression instead of disease initiation. In addition to genetics an assortment of
environmental factors have been proposed in the initiation of RA (Gabriel, 2001;
Heliovaara, 1993; Weyand, 1997). These environmental factors have ranged from viral
and bacterial infections to cigarette smoking (Associates., 1999; Heliovaara, 1993; D.
Hutchinson, Shepstone, L., Moots, R., Lear, J. T., and Lynch, M. P., 2001; Karlson,
1999; Masdottir, 2000). Cigarette smoking, now considered an independent risk factor
for RA, elevates Rheumatoid Factor (RF), an autoantibody that is associated with RA
development (Deighton, 1997; Harrison, 2000; T. Jonsson, Thorsteinsson, J., &
Valdimarsson, H., 1998; Peunte, 1988; Silman, 1996; Uhlig, 1999; Voigt, 1994; Wolfe,
2000). Elevated RF levels can be noted months or even years before the clinical
symptoms of RA (Halldorsdottir, 2000; Heliovaara, 1993; T. H. Jonsson, Steinsson, K.,
Josson, H., Geirsson, A. J., Thorsteinsson, J., Valdimarsson, H., 1998). In the past
decade or so, elevated RF levels have been associated with smoking (Halldorsdottir,
2000; Heliovaara, 1993; T. Jonsson, Thorsteinsson, J., & Valdimarsson, H., 1998; T. H.
Jonsson, Steinsson, K., Josson, H., Geirsson, A. J., Thorsteinsson, J., Valdimarsson, H.,
1998; Masdottir, 2000; Voigt, 1994). Antinuclear Antibodies (ANA), another collection
of autoantibodies that are associated with RA, may also be associated with smoking
1

(Caspi, 2001; Mathews, 1973; Regius, 1988; Saudan-Kister, 1996). ANAs are usually
used as biological markers for specific autoimmune disorders in clinical settings (Center.,
1999; Fritzler, 1986; Harmon, 1985; Hazelton, 1987; Lipsmeyer, 1988; Maddison, 1997;
Pahor, 1998). However, Rheumatologists at the Loma Linda Faculty Medical Offices
(FMO) have noticed that a large percentage of smokers test positive for ANA. To better
understand this phenomenon and possibly determine whether smoking plays a role in the
initiation process of RA, we assessed the association of smoking with ANA and RF
positivity in healthy individuals.
B. Hypothetical Model
Over the years, several RA initiation models have been deliberated in the
literature, with no particular one revealing the true biological mechanism. With RA
being described as a multifactorial disorder it is assumed that both genetic and
environmental elements both play a role in its initiation but in varying degree (Cohen,
1986; Copstead, 1995; Hess, 1988; Ollier, 1995; Rubin, 1995; Weyand, 1997; Zhang,
2001).
In the past decade or so environmental elements such as infectious agents and
lifestyle factors have emerged as possible initiators in the development of RA. Infectious
agents were thought to initiate RA by eliciting RF response, however it has been shown
that in infectious diseases, transient RF levels are produced that may be more beneficial
than detrimental (Newkirk, 2002). In this paper we will focus on smoking, a lifestyle
factor, as a possible initiator.
Although a clear biological mechanism of how smoking could initiate RA
development has not been clearly defined, data from epidemiological and population
2

studies are supporting a hypothesis that has been developed. The hypothesis is that
smoking elevates Rheumatoid Factor (RF) (an autoantibody that is part of an ensemble of
factors that are included in the diagnosis of RA) and the elevated RF levels then increase
the risk of RA development. However, there is another set autoantibodies that are also
now being associated with RA, by way of cigarette smoking. Antinuclear Antibodies
(ANA) are commonly associated with rheumatic autoimmune disorders, but recently they
have been associated with smoking (Caspi, 2001; Mathews, 1973; Regius, 1988; SaudanKister, 1996). If smoking is associated with RF and ANA and both autoantibodies are
also associated with RA, could smoking affect both simultaneously and somehow
increase the risk of RA? To date no one has looked at the effect of smoking on both
ANA and RF. This could be due to the fact that there seems to be two groups of
researchers; those that concentrate on RF and smoking and those who show an
association between ANA and smoking. We attempted to look at the effects of smoking
on both autoantibodies and possibly extrapolate on how they could increase the risk of
RA development.
Our hypothesized model is very similar to the hypothesized model that leans
toward environmental factors as initiators in RA development. We hypothesize that
smoking, a lifestyle factor, produces pathogenic autoantibodies. Although nonpathogenic autoantibodies are part of the normal immune repertoire, pathogenic forms are
not. Autoantibodies become pathogenic when they can illicit an inflammatory response,
which left uncontrolled usually, results in disease. In smokers, we think, pathogenic RFs
and ANAs produced by smoking, over a long period of time could increase the risk of
RA development as shown in figure 1.
3

Figure 1. Hypothetical model of the effects of cigarette smoking on rheumatoid arthritis
initiation.
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Normal transient levels

C. Research Questions
1. Do current smokers, ex-smokers and never smokers show differences in ANA
or RF positivity?
2. Is lifetime smoking history (as pack years smoked) related to ANA or RF
positivity?
3. Do qualitative aspects of cigarette smoking such as tar and nicotine levels
influence ANA or RF positivity?
4. Does second hand smoke exposure, past or current, influence ANA or RF
positivity?

5

CHAPTER 2
LITERATURE REVIEW
A. Literature Review
1. Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory autoimmune
disorder of unknown etiology (Associates., 1999; Cohen, 1986; Copstead, 1995; Odeh,
1997; Rubin, 1995) with an overall population-based frequency of approximately 1% in
white Americans and Europeans and 4% in some tribes of North American Indians, such
as the Pima tribe (Associates., 1999; Criswell, 2002; Gabriel, 2001; Newkirk, 2002).
Even though it can afflict children and adolescents, its incidence increases through the
seventh decade of life, with a 70% female and 30% male distribution in all ethnic groups
(Criswell, 2002; Gabriel, 2001; Newkirk, 2002). In women, RA incidence increases
steadily from the age of menarche to its maximal incidence around menopause (Criswell,
2002; Cutolo, 2000; Kanik, 2000; Wilder, 1996) and in men, the disease incidence
increases rapidly in older men, closely approaching levels seen in women (Cutolo, 2000;
Wilder, 1996).
This chronic disorder is also associated with an increased mortality rate that stems
from complications resulting from infections, malignancies, cardiovascular and renal
diseases as well as treatment-related complications (Criswell, 2002; Gabriel, 2001).
The disease affliction spectrum is highly variable, ranging from a minor selflimiting form to a relentlessly severe progressive joint destruction form, which usually
results in significant physical impairment and social handicap (Associates., 1999; Cohen,
1986; Copstead, 1995; Gabriel, 2001; Hess, 1988; Odeh, 1997; Rubin, 1995; Rugstad,
6

1992; Weyand, 1997; Zhang, 2001). RA is usually characterized by synovial tissue
inflammation, particularly of small joints, which result in the progressive destruction of
the articular cartilage and juxta-articular bone (Associates., 1999; Cohen, 1986;
Copstead, 1995; Gabriel, 2001; Odeh, 1997; Rubin, 1995; Rugstad, 1992; Weyand,
1997). The joint erosions then produce the characteristic deformities and ultimate limited
degree of motion in the affected joints. Even with appropriate drug therapy, 7% of RA
patients are disabled to some extent 5 years after disease onset, and 50% are too disabled
to work 10 years after disease onset (Associates., 1999; Gabriel, 2001).
With more sophisticated types of therapy becoming available, it is becoming more
important to diagnose RA at an earlier stage, so as to prevent the progressive tissue,
cartilage and bone damage that frequently accompanies the disease. It is during the first
period of the disease, when not all clinical parameters are manifest, that specific and
sensitive serological tests are needed. Even more helpful, would be serological tests that
could predict the early phases of RA development, so that preventative measures could be
applied sooner.
Autoantibodies are a common and characteristic feature of rheumatic autoimmune
diseases such as RA. Although their physiological importance in these diseases is not
well understood, their serological levels make them useful tools in diagnosing and
managing rheumatic diseases.
To fully understand the possible initiation process of RA development, a basic
understanding of the inflammation process is required. Inflammation is a host defense
mechanism which is critically involved in fighting infections and other types of tissue
damage. Inflammatory cells also regulate tissue repair and healing. In an attempt to
7

prevent organ destruction, inflammatory cells infiltrate the tissue, gain destructive
properties that can damage the affected organ. Normally the balance between destruction
and repair is carefully regulated however, if the inflammatory process continues
unregulated, disease state is the probable outcome.
2. Hypothesized Etiological Models of Rheumatoid Arthritis
It is likely that RA is really a collection of several diseases which share a
similar clinical phenotype but originate from different or only part shared genetic and
environmental bases (Newkirk, 2002; Ollier, 1995). Several subsets of RA patients have
been considered, however, the largest proportion of patients fall into the erosive (synovial
joints are eroded away) and seropositive for Rheumatoid Factor (RF). Following are
some hypothesized etiological models that may explain this complex disorder.
a. Antigen-Specific Autoimmune Disease. The basic immunological
model for the etiology of RA is much the same as the etiology of any autoimmune
disease. The body normally distinguishes between self and non-self, between proteins
found in the body and proteins carried by bacteria, viruses, fungi and protozoans. When
an immune cell (T or B lymphocyte) reacts to a self-protein during its development in the
thymus or bone marrow, that cell is usually killed or inactivated. In the case of T cells,
some 95% never leave the thymus or bone marrow; instead, most undergo apoptosis
(programmed cell death). But occasionally a self-reactive immune cell, i.e., a T or B
lymphocyte programmed to attack a self-protein escapes destruction and years later it can
be activated and or triggered to elicit an immune response.
When the causative agent first gains access to the joint, it causes an inflammatory
response, with damage to small blood vessels and the accumulation of inflammatory cells
8

(macrophages and lymphocytes). The macrophages process the pathogenetic material
and present it to the lymphocytes, which respond by producing antibodies and cytotoxic
chemicals (B lymphocytes produce antibodies and T lymphocytes produce cytokines that
activate other B lymphocytes and cytotoxins that attack tissue directly). Collagendestroying enzymes are also involved, resulting in an extra-vascular immune complex
disease.
b. Genetic and Environmental Involvement. RA is usually described as a
multifactorial disorder, having both genetic and environmental elements (Cohen, 1986;
Copstead, 1995; Hess, 1988; Ollier, 1995; Rubin, 1995; Zhang, 2001), even though the
boundaries between the two are unclear. Focusing on the genetic involvement, it is well
documented that complex rules apply to common genetic diseases. However, it is known
that in these disorders, a risk threshold is reached when disease-associated genes
accumulate and or combine with other genes (Ollier, 1995; Weyand, 1997).
In RA, it is the multiple genetic determinants, an accumulation of genes encoded
in the HLA (Human Leukocyte Antigen) region, in the major histocompatibility complex,
that are recognized as risk genes and possibly contribute to the risk of chronic
inflammatory rheumatoid synovitis (inflammation of synovial tissue around synovial
joints) (Criswell, 2002; Heliovaara, 1993; Karlson, 1999; Masdottir, 2000; van Boekel,
2002). Recent studies have additionally emphasized that a gene dosing effect for RAassociated, HLA-alleles, are not associated with the disease initiation process but instead
are associated with the progression of the disease (Ollier, 1995; Weyand, 1997). So the
principal role of genetics in RA lies in the progression of the disease rather than in its
initiation.
9

Looking at the environmental involvement, assortments of environmental factors
have been proposed in the initiation of RA. Strong evidence for an environmental
component to disease etiology comes from studies of disease concordance in identical
(monozygotic,[MZ]) twins which show that between 70% and 85% of twin pairs are
discordant for diseases like RA (Cohen, 1986; Copstead, 1995; Criswell, 2002;
Heliovaara, 1993; Hess, 1988; Noort, 1998; Rubin, 1995; Silman, 1996; Zhang, 2001).
Currently, environmental factors that have been associated with RA initiation include
infectious agents (viral and or bacterial) and lifestyle factors such as smoking and
alcohol. Among Viral agents, the Epstein-Barr virus is the most predominant and
streptococcus, mycoplasma and borrelia (the agent of Lyme disease) are the most
common bacterial agents that have been implicated (Associates., 1999; Gabriel, 2001;
Noort, 1998).
Looking at lifestyle factors, specifically smoking, it is now common knowledge
that cigarette smoking influences the immune system. Even though this effect has been
studied extensively, the overall effect is still not fully understood (D. Hutchinson, 2001;
Mattey, 2002; Sopori, 1998; Zeidel, 2002).
3. Effects of Smoke on the Immune System
Cigarette smoking is now the chief avoidable cause of illness and death in
the US, responsible for over 500,00 deaths annually and contributing to about forty
diseases (Services, 1988). In contrast to its many adverse effects, smoking may have
some beneficial effects. Although the detrimental effects of smoking on various organs
have been extensively studied, in the literature, the protective effects have received little
attention. In reviewing these beneficial effects, we are not advocating smoking but rather
10

we are aiding in unlocking the door to a better understanding of all the effects of cigarette
smoking on human diseases.
a. Protective Effects of Smoking. Over the past 20 years it has been well
documented that smoking may confer some beneficial effects in certain circumstances.
In some neurodegenerative disorders, chronic smoking exposure is protective. In
Alzheimer-type senile dementia, smoking is associated with improved mental functioning
and dementia (Mihailescu, 2000). In Parkinson’s disease (PD), besides improving
symptoms, smoking, particularly nicotine has protective effects against its development.
Case-control studies indicate that smoking subjects have one-half the risk of non
smoking subjects in developing PD, whereas follow up studies have shown that the risk
of PD is 20 to 70% more reduced in smokers compared to non-smokers (Mihailescu,
2000).

In inflammatory and immunological disorders, smoking has been found to be
protective against active Ulcerative Colitis (UC), Sarcoidosis, inflammatory acne and
Osteoarthritis (Baron, 1996; Harrison, 2002; Richardson, 2003; Wolfe, 1998). In UC, a
group of British gastroenterologists first noticed the association when they used patients
with colitis as controls in a nutritional study in which smoking habits were considered.
They found that only 8% of 230 patients with UC were current smokers, compared to
44% of matched controls. A meta-analysis performed by Calkins, 1989, also confirmed
this relationship.
The negative association of between smoking and Inflammatory acne (Baron,
1996; Harrison, 2002; Mills, 1993; Wolfe, 1998), was demonstrated in a study by Mills
et. al.1993. In this study, 165 acne patients were questioned on their smoking habits, of
11

which 96 males, 19.7% were smokers compared to a prevalence of 34.5% expected from
national statistics and for females, the prevalence was 12.1% compared to the expected
32.7%.
Another negative association of smoking with a disorder was found unexpectedly
in the first Health and Nutrition Examination Survey (HANES I), where, while studying
the link between radiographically evident knee Osteoarthritis (OA) and obesity and
occupation a modest, statistically significant protective association between smoking and
OA was found, even after statistically adjusting for age, sex and weight (Anderson, 1988;
Felson, 1989; Harrison, 2002). While assessing aspects of behavior related to oral
contraceptive use on the onset of RA, Hazes et al., 1990 surprisingly found cigarette
smoking and alcohol consumption to be protective for RA development, independent of
oral contraceptive use. These results contradict the majority of results in this area, which
all support the notion that smoking is a risk factor for RA development (Harrison, 2002,
2000; Heliovaara, 1993; D. Hutchinson, 2001; D. Hutchinson, Shepstone, L., Moots, R.,
Lear, J. T., and Lynch, M. P., 2001; T. Jonsson, Thorsteinsson, J., & Valdimarsson, H.,
1998; Karlson, 1999; Mathews, 1973; Mattey, 2002; Saag, 1997; Silman, 1996; Sopori,
1998; Voigt, 1994; Wilson, 1999).
b. Detrimental Effects of Smoking. Despite evidence that smoking can
have beneficial effects there is substantially more evidence implicating smoking in either
disease onset or progression through hormonal changes and or suppression of numerous
immunological components. For example, it’s been documented that androgens and
estrogens modulate susceptibility and progression to autoimmune rheumatic diseases
(Barrett, 1999; Cutolo, 2000; Kanik, 2000; Nelson, 1997; Silman, 1992; Wilder, 1996).
12

Androgens seem to primarily suppress cellular and humoral immunity, whereas estrogens
seem to enhance humoral immunity.
Looking at immunological components, immune dysfunctions have been reported
in smokers, with abnormalities in T-lymphocytes (George, 1997; Harrison, 2002; Noort,
1998; Schaberg, 1997; Sopori, 1998; Zeidel, 2002), cytokines, by-products of Tlymphocytes that are released in response to inflammation (Francus, 1992; George, 1997;
Noort, 1998; Sopori, 1998; Zeidel, 2002), natural killer cells (George, 1997; Harrison,
2002; Sopori, 1998; Zeidel, 2002) and neutrophils (George, 1997; D. Hutchinson, 2001;
Sopori, 1998) and autoantibodies (Caspi, 2001; Mathews, 1973; Regius, 1988; SaudanKister, 1996), antibodies against various self-components including the nucleus and its
components.
Antinuclear Antibodies (ANA), antibodies against the nucleus and its
components, were classically differentiated from autoantibodies, however, due to
increased sensitivities in immunological tests, it is now quite clear that cellular antigens
outside the nucleus are also targets of autoantibody production in several rheumatic
disorders (Smolen, 1998; Sontheimer, 1991; Tan, 1989).
These subsets of autoantibodies were first thought to be a consequence of tissue
destruction due to external agents (Grabar, 1975), however, they are now considered to
be part of the repertoire of a healthy immune system (Pisetsky, 1987; Smolen, 1998; Tan,
1989). As part of a healthy immune system, ANAs aid in host defense mechanisms, by
facilitating in the removal of various foreign antigens (Pisetsky, 1987) and products
resulting from tissue or cell destruction (Grabar, 1975; Rugstad, 1992; Smolen, 1998;
Tan, 1982, 1989; Williams, 1994).
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The origin of ANAs appears to differ for each subclass of ANA, but involvement
of distinct cellular and molecular mechanisms are suggested (Pisetsky, 1987). For
example, precursors for anti-DNA antibodies (a subclass of ANA associated with
Systemic Lupus Erythematosus) are uniformally distributed among B cell populations.
The role of ANAs in disease pathogenesis is still unclear but it is thought that they
become pathogenic when they form immune complexes in the circulation or in the
affected organ and elicit an inflammatory response via complement activation.
Complement activation then mediates the observed tissue injury in the affected area
(Pisetsky, 1987; Tan, 1982, 1989). In rheumatic disorders these pathogenic
autoantibodies are a common and characteristic feature. Many are used as diagnostic
tools in the confirmation and management of the disease. For instance, a positive
Rheumatoid Factor (RF) test is part of an ensemble of factors that are included in the
American College of Rheumatology criteria for its diagnosis (Newkirk, 2002; Ollier,
1995; Suarez-Almazor, 1998).
In the past fifteen years, epidemiological and prospective studies have shown
smokers to be at a higher risk of RA development possibly related to the elevation of RF
(Harrison, 2000; Saag, 1997; Silman, 1996; Voigt, 1994; Wolfe, 2000). Because of this
smoking is now considered a risk factor for RA development (Criswell, 2002; Deighton,
1997; Harrison, 2000; T. Jonsson, Thorsteinsson, J., & Valdimarsson, H., 1998; Silman,
1996; Uhlig, 1999).
Antinuclear antibodies (ANAs) are also causing interest in the development of
RA, by way of cigarette smoking yet, studies of ANA and smoking are limited. All of
the studies we were able to find (Caspi, 2001; Mathews, 1973; Regius, 1988; Saudan14

Kister, 1996), ANA was associated with smoking, in that smokers were at a higher risk of
having elevated ANA levels.
c. Effects of Smoking on Rheumatoid Arthritis Development. Cigarette
smoking is a strong predictor of seropositive RA. Three prospective cohort studies and
two population based case control studies have shown that cigarette smoking can increase
a person’s risk for developing RA (Heliovaara, 1993; Saag, 1997; Silman, 1996; Voigt,
1994). One retrospective cohort study in female health workers showed a 49% increased
risk for seropositive RA in women who smoked 25 cigarettes a day for more than 20
years (D. Hutchinson, Shepstone, L., Moots, R., Lear, J. T., and Lynch, M. P., 2001;
Karlson, 1999) and another study performed in males showed similar findings. Current
smokers had the highest relative risk compared to ex-smokers and non-smokers and the
high relative risk in ex-smokers in relation to never smokers persisted over 14 years and
even increased with time (Heliovaara, 1993; Voigt, 1994).
The onset of clinically manifest RA is often preceded by elevated Rheumatoid
Factor (RF) (T. Jonsson, Thorsteinsson, J., & Valdimarsson, H., 1998). Although its role
in RA pathogenesis is still unclear, RF is thought to perpetuate and amplify the synovial
inflammatory process. Indeed, studies of patients with elevated RF, either in healthy
individuals (Halldorsdottir, 2000; Heliovaara, 1993) or in those with RA (Wolfe, 2000)
illustrate that smokers are significantly more likely to have elevated RF. The presence of
persistently positive RF in healthy individuals is important, because the persistent
positivity can increase the risk of RA seropositivity by 7-fold (D. Hutchinson, 2001).
This then leads to another question: would the number of cigarettes smoked or duration
of smoking also affect RF positivity.
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The quantification of cigarettes smoked is important because it gives a more
comprehensive over view to the relationship between smoking and RA development.
With this in mind, dose dependent associations between pack years and RA have been
documented (Heliovaara, 1993; D. Hutchinson, Shepstone, L., Moots, R., Lear, J. T., and
Lynch, M. P., 2001). Additionally, population studies as well as epidemiological studies
have again demonstrated this dose-response relationship, with the relationship increasing
a person’s risk for RA development.
Although an observational study by Wolfe also showed this dose-response
relationship, methodological issues in cross-sectional studies may have influenced the
results, since disease onset may have influenced smoking habits, which may then have
lead to a false dose-response association. A prospective study would eliminate this error
and give a more accurate picture concerning the effects of smoking on disease outcome.
Prospective studies in Finland and the Netherlands by Halldorsdottir and Jonsson
replicated this same dose-response relationship. In addition to showing a dose response
relationship, Jonsson, Thorsteinsson and Valdimarsson, 1998, showed that smokers were
more likely to persistently have elevated IgA and IgM RF isotypes compared to
nonsmokers. The fact that elevated RF levels are reported to appear months or even
years before the actual clinical onset of RA (T. H. Jonsson, Steinsson, K., Josson, H.,
Geirsson, A. J., Thorsteinsson, J., Valdimarsson, H., 1998; Peunte, 1988), indicates that
factors regulating RF production such as cigarette smoking may play a primary role in the
pathogenesis of RA. However, one of the major problems in determining a specific
mechanism for the role of RF in the pathogenesis for RA in smokers is that the lag time
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between previous smoking and the actual clinical onset of RA can take decades, so
conceptualizing a possible mechanism is difficult.
4. Rheumatoid Factor
a. Relevance of Rheumatoid Factor. Rheumatoid Factor (RF) was first
identified by Waaler in 1940 (Cohen, 1986) and since then a tremendous amount of work
has been performed on the incidence, nature and specificity of these autoantibodies.
Rheumatoid Factors are autoantibodies that react with an individual’s own
immunoglobulins, interacting predominately with the Fc portion of immunoglobulin G
(IgG). Although these autoantibodies belong to most of the immunoglobulin classes, in
Rheumatoid Arthritis patients, IgA, IgG and IgM are the predominate ones (Associates.,
1999; Davis, 1986; Hess, 1988; T. H. Jonsson, Steinsson, K., Josson, H., Geirsson, A. J.,
Thorsteinsson, J., Valdimarsson, H., 1998; Rugstad, 1992; Suarez-Almazor, 1998; Zhang,
2001).
The most studied form of RF are those that bind to the Fc portion of IgG, that
now they are the only established serological marker for RA (Newkirk, 2002; Steiner,
2002; van Boekel, 2002), with about 70 to 80% of RA patients testing positive for it (D.
Hutchinson, 2001; Peunte, 1988).
Despite this establishment, the specificity of RF positivity is limited as it is
detected in several populations. In the healthy population 3-5% test positive, and 10-30%
healthy elderly individuals test positive (T. H. Jonsson, Steinsson, K., Josson, H.,
Geirsson, A. J., Thorsteinsson, J., Valdimarsson, H., 1998; Steiner, 2002; SuarezAlmazor, 1998). Patients with other rheumatic diseases besides Rheumatoid Arthritis
(RA), such as Sjogren’s syndrome (SS), Mixed Connective Tissue Disease (MCTD) and
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Scleroderma (Davis, 1986; Deighton, 1997; Harrison, 2000; T. Jonsson, Thorsteinsson,
J., & Valdimarsson, H., 1998; Newkirk, 2002; Steiner, 2002; Suarez-Almazor, 1998; van
Boekel, 2002; Wolfe, 2000) are also known to frequently test positive for RF.
RF positivity is also induced by certain infectious agents, however in most cases
the RF response is transient and rarely develops into acute arthritis (Newkirk, 2002). In
cases where the RF response is transient, RF may be more beneficial then detrimental
since it contributes to the clearance of immune complexes and so aids in the hosts
defense system (Newkirk, 2002).
b. Role of Rheumatoid Factor in Rheumatoid Arthritis. The diagnosis of
most musculoskeletal disorders is generally based on clinical presentation with laboratory
tests either confirming the diagnosis or predicting it (Cruz, 2002; Suarez-Almazor, 1998).
In many autoimmune diseases, clinical features arise from tissue inflammation and so an
inflammatory response may be detected on routine tests (Cruz, 2002).
The role of RF in Rheumatoid Arthritis is more detrimental compared to its
beneficial role in infectious diseases. Hutchinson (2001) gives a few possible
mechanisms by which RF could influence RA initiation and progression. For instance,
one of the functions of RF is to induce neutrophils to release their contents, which are
capable of degrading connective tissue matrix (Blackburn, 1986). Smokers also have
primed neutrophils that additionally release more free radicals that also have tissue
damaging properties. In patients with erosive RA, large numbers of neutrophils, with
tissue damaging properties, are present in the synovial effusions (fluid that produced by
synovial structures). So smokers who develop the erosive type of RA may have a
predominantly neutrophil-driven disease.
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Another possible mechanism could involve RF activating inflammatory
responses. RF already has a physiological role of improving immune complex clearance;
however, in its pathogenic role the formed complexes may activate inflammatory
processes in the various tissue compartments of the synovial joint. The larger complexes
move into the joint fluid while the smaller ones, the more soluble and least pathogenic,
spill over into the general circulation. The larger complexes in the synovial joints then
initiate the inflammatory response by activating the complement system which increases
the vascular permeability and uptake of immune complexes by leukocytes, which in turn
release a series of products that further injure the surrounding tissue. Activated
macrophages, and other inflammatory associated cell types stimulate the production of
cytokines, which additionally amplify the inflammatory response (Copstead, 1995;
Rubin, 1995; Rugstad, 1992; Smolen, 1998) that eventually renders the affected joints
and synovial tissue more susceptible to destruction.
It is also possible that in smokers who develop RA, the disease process is
transformed by the presence of elevated RF, which if not for the smoking history might
never have been present.
c. Rheumatoid Factor Isotypes. At a subcellular level, RF can be broken
down into several isotype groups with each isotype being associated with certain
disorders. IgA and IgM RF isotypes are almost exclusively found in diseased RA
patients but recently they’ve been seen in smokers (CDC, 1999). A prospective study by
Halldorsdottir et al in the Netherlands, demonstrated that participants with increased IgA
and IgM RF isotypes were 10 times more likely to develop RA when compared to those
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who were seronegative for RF or to those who just had persistently increased RF isotype.
Eberhardt et al also confirmed this finding.
5. Antinuclear Antibodies
a. Relevance of Antinuclear Antibodies. Other autoantibodies that are
now being implicated in the development of RA are Antinuclear Antibodies (ANA).
These autoantibodies differ from Rheumatoid Factor (RF) in that they react specifically
with nuclear components of the cell such as DNA, RNA, nucleoli, histones and non
histone proteins, (Fox, 1981; Tan, 1982; University of Washington, 1999) instead of
immunoglobulins as is the case with RF.
While antibodies to nuclear components are present in many immunological
conditions, their primary significance lies in the clinical diagnosis and management of
systemic rheumatic diseases (Fritzler, 1986; Gardner, 2000; Hazelton, 1987; Lipsmeyer,
1988; Maddison, 1997; Pahor, 1998; Tan, 1982). Usually, they have been associated
with Systemic Lupus Erythematosus (SLE) however in reality they are proficiently
produced in many autoimmune disorders. For example chronic inflammatory systemic
rheumatic disorders such as Scleroderma, Mixed Connective Tissue Disease (MCTD)
and RA each have distinct ANA patterns that help in confirming the initial diagnosis
(Cohen, 1986; Harmon, 1985; Pisetsky, 1987; University of Washington, 1999). To a
smaller extent pathological autoantibodies have resulted from viral and bacterial
infections (Cohen, 1986; Tan, 1982).
High titers of specific antinuclear antibodies or the presence of particular
antibodies can aid in distinguishing specific disorders. For example high titers of AntiRNP (ribonucleoprotein) antibodies are generally found in mixed connective tissue
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disease, whereas varying titers may be found in SLE and other rheumatic diseases with
no clinical significance (Harmon, 1985; University of Washington, 1999). The presence
of anti-DNA or anti-Sm antibodies (Sm stands for Smith, the name of the patient in
whom the antibody was first identified) usually confirms the diagnosis of SLE. To
confirm a diagnosis of autoimmunity, an ANA reflexive panel, is usually ordered
(University of Washington, 1999), with distinct ANA profiles existing for specific
diseases. Positive results from this panel may then determine whether an individual is
referred to a Rheumatologist.
b. Antinuclear Antibodies and Rheumatoid Arthritis. In many systemic
rheumatic diseases, the frequency of disease specific ANA production is extraordinarily
high that interest in this area has gained momentum (Tan, 1982), however, to date no
specific mechanism of ANA production has been clearly formulated. In RA patients, 10
to 70% will test positive for ANA in varies series (Caspi, 2001; Fritzler, 1986; Gardner,
2000; Harmon, 1985; Hazelton, 1987; Lipsmeyer, 1988; Steiner, 2002). In the normal
population, however, only 5% test positive, with the level of positivity increasing sharply
over the age of 40. Some studies have even reported an incidence of 50 to 60% positivity
in persons over 60 years of age. Within persons who test positive for ANA, the elderly
and male populations (Associates., 1999; Center., 1999; Cohen, 1986; Juby, 1994)
usually test at higher titers. Studies that have specifically looked at ANA and RA, have
on the most part evaluated the impact of ANA on disease outcome. For example Meyer
et al, 1997, showed that RA patients with elevated ANA had a poorer diagnosis in
regards to radiological outcomes. We were unable to find studies that assessed the
impact of ANA on the initiation or development of RA.
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c. Antinuclear Antibodies and Smoking. From the literature, Mathews,
Whittingham, Hooper and Mackay (1973) were really the first to evaluate the association
between smoking and ANA. Apparently healthy, smokers were compared with healthy
non-smokers on elevated ANA levels. Using stratified analysis, the authors found an
association between smoking status and ANA in men of all ages. A detailed analysis
further showed that for males, the increased risk of ANA was seen in cigarette smokers
but not in pipe or cigar smokers. A similar relationship was also found in women
although it was at a slightly lower relative risk. After comparing smokers to nonsmokers,
the authors then focused on smokers to see if a dose-response relationship was present.
Again using stratified analysis a dose-response relationship was found.
Using an older population, Regius, et al., (1988) replicated this finding, however,
the presences of ANA was more frequent in females than in males.
6. Summary
RA has been described as a multifactorial disorder with both genetic and
environmental elements playing a role in its initiation to varying degree. Environmental
factors play a major role in the initiation of the disease while genetic factors are now
thought to play a major role in the progression of the disease.
In the past decade or so environmental elements such as infectious agents and
lifestyle factors have emerged as possible initiators in the development of RA. Infectious
agents were thought to initiate RA by eliciting RF response, however in infectious
diseases, transient RF levels are produced to aid in the clearance of immune complexes
(Newkirk, 2002).
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Although a clear biological mechanism of how smoking could initiate RA
development has not been clearly defined, data from epidemiological and population
studies are supporting a hypothesis that is being developed, which states that smoking
elevates Rheumatoid Factor (RF), which then increases the risk of RA development.
Another set of autoantibodies that are also now being associated with RA, by way
of cigarette smoking, are ANA. Elevated ANA levels are commonly associated with
rheumatic autoimmune disorders, but recently they have been associated with smoking.
If smoking is associated with RF and ANA and both autoantibodies are also associated
with RA, could smoking affect both and somehow increase the risk of RA?
To date no one has looked at the effect of smoking on both ANA and RF. This
could be due to the fact that there seems to be two groups of researchers; those that
concentrate on RF and smoking and those who show an association between ANA and
smoking. We attempted to look at the effects of smoking on both autoantibodies.
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CHAPTER 3
RESEARCH DESIGN AND METHODS
A. Study Design
A retrospective cross-sectional study was done, where consenting participants
first answered the standard Blood bank questionnaire then additionally answered the
study questionnaire (Appendix F). The questionnaire included general demographic
information, known variables associated with ANA and RF positivity and a detailed
smoking history section. An additional 2 ml of blood was also collected during the blood
donation phase and later the samples were analyzed for ANA and RF positivity.
/. Participant Characteristics
Informational sheets (Appendix D) about the study were used to recruit
582 volunteer blood donors, from two donation sites, the San Bernardino blood bank, and
the Riverside blood bank. The American Association of Blood Bank (AABB) guidelines
were applied to all blood donors. According to these guidelines to be eligible to donate a
volunteer must be at least 17 years old (although some states permit younger people to
donate with parental consent); be in good health; weigh at least 110 pounds and be no
older than 80 years.
A good estimate of the refusal rate could not be obtained for several reasons.
Because of the logistics of the study, the research coordinator was in the recovery
cafeteria helping participants answer the study questionnaire, while the front desk
personnel informed prospective participants about the study. Days on which the front
desk personnel were busy, prospective donors may have not been informed about the
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study. Even though the blood bank keeps records on the number of donors per day,
filtering out return donors would have been difficult.
To prevent repeat donors from participating in the study again, the informational
sheet stressed the study was a one time event and the front desk personnel additionally
asked prospective donors whether they had participated in the study on their last visit.
Cases missing data on all of the relevant variables, the dependent variables; ANA
and RF positivity (n=6), the independent variables; smoking status (n=8) and pack years
(n=l 1) and the covariate variables; age and gender (n=8) were eliminated from the
analysis dataset. Based on patterns on how participants answered on the above variables,
imputations were performed to replace missing data, by using other variables in the
analysis dataset.
For example if cases were missing on smoking status, other variables such as age
started smoking, age stopped smoking and are you currently smoking were used to
impute smoking status. Participants who reported they smoked but did not report their
approximate number of packs smoked per day were eliminated since we could not create
or impute from other variables the pack year variable. In total 33 cases were removed
from the analysis dataset due to missing data. The demographics of the participants are
presented in table 1.
2. Exclusion Criteria
Using the blood banks exclusion criteria (Appendix A), participants were
additionally excluded on systemic rheumatic conditions associated with ANA and RF
levels. Participants who smoked cigars (rc=10), pipes (n=7), chewed sniff (ti=1) or used
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any combination of the three (72=8), were eliminated from the analysis dataset. So in total
59 cases were removed from the analysis dataset, leaving us with 523 cases.
3. Inclusion Criteria
Participants included in our analysis were volunteer blood donors from the
San Bernardino and Riverside blood bank sites who fully completed both the standard
blood bank questionnaire and the study questionnaire.
4. Questionnaire
a. Questionnaire Content. Variables that had been shown to potentially
affect ANA, RF and smoking exposure were used to develop the six sections in the study
questionnaire. General demographics, the first section gave us an idea of our study
population as well as helped determine the generalizability of our results. A brief
medical history followed that allowed us to further exclude subjects who had variables
that were associated with positive ANA and RF.
A detailed smoking history section followed. Here we assessed amount, duration.
past and current smoking exposure. Currently, as there are no clear theories on smoking
exposure in relation to ANA and RF positivity, assessing amount, duration and past and
current smoking exposure gave us a better picture of any possible relationship that
showed up.
Alcohol consumption was the next section, where questions on past and current
alcohol use were asked. The following section, female history, concentrated on natural
and artificial estrogen and progesterone levels. Deficient levels of estrogen and
progesterone have been implicated in the initiation of RA onset, and excess levels of both
hormones have been shown to delay RA onset, whether natural or artificial.
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Tablel. Participant Characteristics
Participants
N
%

Demographics
Sex
Male

304

58.13

Female

219

41.87

Black/African American

20

3.82

Caucasian

427

81.64

Hispanic / Latino

73

13.96

Native American

11

2.10

Asian or Pacific

12

2.29

Other

6

1.15

Ethnicity*

♦Percentages for ethnicity add up to more than 100 because individuals
were allowed to choose more than one ethnicity
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Tablel. Participant Characteristics Cont...
Participants
N
%

Demographics
Education
Below high school

15

2.87

High school diploma

181

34.61

Trade school diploma

49

9.37

Associate degree

94

17.97

Bachelors degree

113

21.61

Masters degree

54

10.33

Doctoral degree

17

3.25

Never smokers

290

55.45

Ex-smokers

180

34.42

Current smokers

53

10.13

Mean

SD

48.3

14.1

Smoking Status

Age at questionnaire submission
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Finally the last section of the questionnaire looked at physical activity. Data
from the last three sections of the questionnaire were collected as part of future projects
and none were included in the analysis dataset.
b. Pilot Testing. A sample questionnaire was developed by the research
coordinator and evaluated by Rheumatologists at the Faculty Medical Offices, (FMO),
faculty members on the dissertation committee and the research committee at the San
Bernardino blood bank. The final draft was then pilot tested at the San Bernardino blood
bank, to test the questionnaires readability and comprehensiveness. Five to six
participants were approached in the recovery canteen at the start of their required 15
minute break.
5. Procedure
a. Registration. Prospective donors at the registration desk were first
given the American Association of Blood Banks (AABB) pamphlets to read and a
consent letter (Appendix E) that acknowledged in writing the information was thoroughly
understood. The pamphlets informed the donors on the risks of transmitting infectious
diseases by blood transfusion and also on the signs and symptoms of AIDS.
As part of the reading material, an information sheet (Appendix D) about the
study was also added. It briefly explained the study and requested two things; permission
for the use of an aliquot of blood and consent to later answer a second questionnaire, the
study questionnaire. Participants that agreed to take part in the study were then given the
consent and the study questionnaire.
b. Screening. Prospective donors that did not self-defer were given a
detailed blood bank health history questionnaire followed by an abbreviated physical
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exam. Information from the detailed health history questionnaire allowed the screening
personnel to include potential participants and exclude those with factors listed under the
blood bank’s exclusion criteria (Appendix A). To ensure that all donors at each site
provided the same information, a uniform donor history questionnaire was used. For our
study this questionnaire acted as a screening tool eliminating persons who had systemic
rheumatic diseases.
The abbreviated physical examination checked blood pressure, pulse, temperature
and anemia. The anemia check was performed on a drop of blood taken from a finger or
an earlobe. Abnormalities that corresponded to the blood banks exclusion criteria
resulted in an automatic deferral. In such cases, the study questionnaire and consent
letter were returned to the registration desk.
c. Donation Process. Volunteers that qualified for donation then carried
the consent letter and the study questionnaire, with the rest of their paper work into the
donating room. Here phlebotomists labeled the designated test tubes with a set of
detachable random numbers, which were pealed off, from the front page, top right hand
comer of the study questionnaire. A duplicate set of the numbers still attached to the
questionnaire enabled us to connect each questionnaire to each blood sample.
d. Questionnaire Distribution. Even though the registration personnel
handed the study questionnaire to participants, whole blood donors and plasma / platelet
donors both answered their questionnaires differently. Since whole blood donors
usually took 30 minutes to donate, and had to wait 15 minute after their donation before
they could leave, self-administered questionnaires were performed during this recovery
period. However, plasma and platelet donors usually took an hour or so to donate and
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since their blood volume remained more or else the same, they were not required to wait
the mandatory 15 minutes after donation. To use their time efficiently, the research
coordinator performed interview-assisted questionnaire administrations.
The first two weeks of the data collection phase were the busiest, where we
ranged between 15-57 participants per day. For the duration of the third and fourth week.
8-21 participants per day agreed to take part in the study and for the fifth to the seventh
week, the number of participants decreased as the blood bank imposed a donor limit that
allowed only 20 donors a day. During this phase, we ranged between 4-19 participants
per day. At the start of the eighth week the imposed limit was removed and the number
of participants/ day increased slightly to 5-22 participants per day and for the last two
weeks of the data collection phase, we moved from the San Bernardino site to the
Riverside site. Here 5-14 participants per day agreed to be part of the study. In total 36
days were required to collect 583 questionnaires, from which 177 participants were
smokers and 399 were never smokers.
B. Blood Samples
From each participant, an extra, tube of blood was drawn for the study. Collected
samples were spun down and the separated serum stored in a minus 70° degree freezer.
Once all the serum samples were collected, they were transported in a portable ice chest
to the Internal Medicine Laboratory at Loma Linda Medical Center. Here they were
tested for ANA and RF positivity. ANA positivity was tested using the indirect
fluorescent antibody test method and the latex agglutination test was used for RF
positivity.
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C. Ethical Issues
1. Risks
The main risk of the study was confidentiality of the patient’s information
from the study questionnaire. Using a consent letter developed from the Loma Linda’s
Institutional Review Board (IRB) guidelines and later approved for usage by the same
body, the letter explained the study and stressed confidentiality of any information that
was given. The patient’s name or personal identifiers did not appear on any of the
information that was collected.
Blood samples were collected at the blood bank, so their protocol on blood
drawing was followed. The only possible risk that could have occurred would have been
low blood volume, symptoms of which include feeling faint and weak. However, as
participants were required to wait 15 minutes and drink at least 8 fluid oz of fluid of
juice, after donation these symptoms were greatly reduced.
2. Benefits
Participants of the study did not gain any direct benefits; however,
providing necessary information to a study that may eventually help others should
produce a sense of humanitarianism, which in itself is reward enough.
D. Analysis
1. Power Calculation
The analysis used to test our primary hypothesis was logistic regression.
Based on Hsieh’s (1989) estimation tables for logistic regression, power = 70% and an
Odds ratio (OR) OR = 2.0 we needed 169 smokers to detect the association between
smoking exposure and ANA. As expected, 20% of the donors were smokers, so a total
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sample of (169 x 5) 845 questionnaires and blood samples should have been collected.
However, out of the first 576 questionnaires that were collected, 177 of them were
cigarette smokers. We had reached and surpassed our required number of smokers. The
data collection phase was then ended.
The effect size for ANA, in this part of the power calculation was derived from
Mathew, J. D., Whittingham, S. W., Hooper, B., Mackay, I. R. 1973 paper on The
Association of Autoantibodies with Smoking, Cardiovascular Morbidity, and Death in the
Busselton Population. The paper compared elevated ANA levels of smokers to nonsmokers.
To detect the association between smoking and RF, based on Hsieh’s (1989)
estimation tables for logistic regression, power = 70% and OR = 2.5, 108 smokers were
needed and as 20% of the donors were assumed to be smokers, (108 x 5) 540
questionnaires and blood samples should have been collected. However, as 177 smokers
were collected, this number was more than sufficient for this part of the analysis. An
effect size of 2.5 for the OR was used for this part of the analysis. It was derived from
Jonsson. T, Thorsteinsson. J, and Valdimarsson. H., 1998 paper “Does smoking stimulate
rheumatoid factor production in non-rheumatic individuals”. The OR was calculated
from a 2x2 table that looked at the relationship between smoking and persistent RF
elevation.
2. Independent Variables
To reveal the clearest biological relationship between the exposure and
outcome variables, the exposure variable, smoking, was first defined as a categorical
variable called smoking status, then as a continuous variable. As a categorical variable,
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we assessed whether a dose response relationship existed among never smokers, ex
smokers and current smokers and then as a continuous variable we considered whether
quantity and duration had an effect on the outcome variables. Second hand smoke
exposure was also assessed in relation to ANA and RF positivity.
a. Smoking Status. Never smokers and current smokers were created
using the following two questions “Have you ever smoked?” and “Are you still
smoking?” Participants, who answered no to both or no to the first and missed the second
question were coded as never smokers and those who answered yes to both were coded as
current smokers.
Ex-smokers were created using four questions in total. Using the two above
questions, if participants, answered yes to the first and no to the second or it was missing,
they were coded as ex-smokers. If participants missed both, two additional questions
were used to assess their smoking status; “At what age did you start smoking?” and “At
what age did you stop smoking?”
b. Pack Years. Seven questions were used that asked participants the
approximate number of packs per day they typically smoked in seven periods of their
lifetime, where the first period was a year and the last was nineteen years. For each of
the periods participants were asked to estimate the approximate number of packs smoked
per day. To obtain an estimate of the packs smoked in each period, the number of years
in each period was multiplied by the reported packs smoked per day in that period.
Summing the estimates across all seven periods, gave us the pack years variable. For
cases that did not indicate a number of packs smoked in a period but did indicate smoking
for some period, we assumed they had not smoked in that period and coded them as zero.
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For participants who smoked for more than sixty years, an extra term, the estimate
of packs smoked over sixty, was added to the pack year equation. This estimate was the
product of the years smoked over sixty with the reported number of packs per day
smoked in that period.
The pack years variable was strongly positively skewed, in that a large percentage
of our subjects were never smokers, because of this, pack years was categorized into a
four level variable and that categorization used in most of our analyses
c. Second Hand Smoke. To determine whether past or current second
hand smoke would make a difference on ANA and RF positivity, we divided second hand
smoke exposure into two categories, past and current second hand smoke exposure. Past
second hand exposure was created using the following question from the study
questionnaire; When you were child who smoked in your household? The responses were
coded based on the number of persons who were smoking in the household. For example
if only one person smoked in the house, then past second hand smoke was coded as one.
If two persons smoked in the house, then past second smoke was coded as two and so on.
Current second hand smoke was created using the following question from the
study questionnaire; Do your household members, friends, co-workers smoke? The three
categories were coded as separate questions with the same three levels of exposure to
choose from. The levels of exposure were coded as; zero for non-exposure, one for
minimal exposure and two for moderate exposure. Summation of the levels of exposure
across the three questions was then defined as current second hand smoke. In other
words current second hand smoke was the summation of the exposure levels for
household members, friends and co-workers for each case.
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So if a participant was exposed to moderate and minimal smoke exposure from
household members, friends and co-workers their current second hand smoke score
would be nine, the highest score. However, if participants were not exposed to any
second hand smoke their score would be zero, the lowest score.
d. Tar and Nicotine. It was usually difficult to assess the level of nicotine
and tar from the study questionnaire questions, as in the majority of cases nicotine and tar
levels were not written on the cigarette packets. To overcome this dilemma and obtain
more accurate values, we used The Report of Tar, Nicotine, and Carbon Monoxide
Content of the Smoke of 1206 Varieties of Domestic Cigarettes for the year 1994
(Commission, 1994). With this report, a separate database was created where the
cigarette brand names and their corresponding nicotine and tar levels were entered. By
matching on cigarette brand name, tar and nicotine, we replaced missing tar and nicotine
levels in the analysis dataset. To determine the level of nicotine and tar a person smoked
we multiplied each respective level to the pack year variable.
e. Dichotomous Second Hand Smoke. This was created using the current
second hand smoke exposure variable, where we simply collapsed and recoded responses
that were greater than zero as one and defined them as exposed and responses that were
equal to zero were defined as non-exposed.
3. Dependent Variable
The outcome variables were ANA and RF positivity. To test for ANA
positivity, the indirect fluorescent antibody test (Appendix H) was used. Titers less than
1:40, were considered negative and titers 1:40 and above were merged together and
considered positive. ANA positivity was then operationally defined as a dichotomous
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variable. To test for RF positivity, the latex agglutination test (Appendix I) was used.
Titers less than 1:2 were considered negative and titers 1:2 and above were merged
together and considered positive. This was done because inadequate positive cases were
detected at higher titers. RF positivity was then also operationally defined as a
dichotomous variable. All positive serums were reported with their titers.
4. Potential Confounders
Based on the literature two main variables were associated with elevated ANA
and RF. Older males were more likely to have elevated ANA and RF (Cohen, 1986;
Mathews, 1973; Regius, 1988) and since we want to observe the main effects of smoking
on ANA and RF the effects of both age and gender were removed by treating them as
covariates in the binary logistic regression models.
a. Current Age. This was created using the following two questions from
the study questionnaire. The first asked the participants to fill in the date they took the
questionnaire and second asked for their date of birth. Current age was then coded by
subtracting the participant’s date of birth from the date they answered the questionnaire.
b. Gender. This was easily coded as a dichotomous variable. Other
potential confounders that have been associated with RA development, but not with ANA
or RF elevation directly, include; race, estrogen and progesterone (natural or artificial)
variations and alcohol consumption. Caucasians compared to other races (Hess, 1988;
Rubin, 1995) are more prone to RA development and deficiencies in estrogen and
progesterone levels are suspected to modulate susceptibility by either; regulating disease
onset, disease severity and disease progression (Barrett, 1999; Cutolo, 1998; Kanik,
2000; Nelson, 1997; Silman, 1996; Wilder, 1996).
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Artificial estrogen and progesterone, in the form of oral contraceptives, have also
been associated with RA. A meta-analysis performed by Romieo et al, in 1989,
consisting of 12 studies from four countries, showed a small non-significant protective
effect against RA development. However, in 1997, Brennan et al, showed that only
current oral contraceptive users had this protective effect.
Regular alcohol consumption has been shown to be a positive risk factor for RA
(Goldberg, 1999) and physical activity is known to induce changes in circulating immune
function (Shephard, 1997) that would appear helpful in regulating inflammatory
responses in the synovial fluid of RA patients.
Although there is no literature showing the potential confounders to be directly
associated with ANA and RF, we still examined their association to ANA and RF, via
univariate analysis. Variables that showed an association were added to our models and
controlled for statistically.
5. Statistical Analysis
To describe the quantitative and qualitative relationships between the
exposure variable, and the outcome variables, univariate analyze and multivariate models
were performed using SPSS version 10.0. Chi-squared tests were performed in the
univariate analyzes, where the exact test for significance (Cyrus, 1994) was used to test
for significance. In situations where the exact test was not possible, the Monte Carlo test
was used instead. Binary logistic regression models were used for the multivariate
models because the outcome variables were dichotomous and their distributions were
non-linear in relation to the exposure variable. Significant interactions from the models
were graphed to assist in their interpretation.
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6. Sensitivity Analysis
Smoking history was self-reported, so its validity even with anonymity
becomes questionable. Smokers wanting to fit in with the current social norm of not
smoking could have under-estimated the actual amount they smoked or misclassified
themselves. So smokers could have categorized themselves as never smokers and never
smokers misclassified themselves as smokers (Patrick, 1994). To account for this, an
analysis of the effects of misclassification was performed. Based on Patrick et al’s metaanalysis” of 23 studies with similar populations (general population) and study designs
(observational) the median false positive (3.3%) and the median false negative (9.4%)
error rates were calculated. Median values were used to calculate the error rates so as to
reduce the impact of a few extreme cases in the collection of studies. Although the paper
is about 10 years old, and the data used in the paper is probably another 15 to 20 years
old, then the error rates we derived using this data may not be reflective of current
smoking rates. Nevertheless, these represent the best available error rates that we could
use in our sensitivity analysis.
To obtain the adjusted OR values we first determined the adjusted counts for each
cell in a 2 x 2 table. To do this we assumed that there were no errors in the qualitative
testing of ANA and then using the false positive and false negative misclassification error
rates we derived two algebraic equations for each cell in the 2 x 2 tables.
Two sets of equations were used to solve for the adjusted counts in each cell after
the misclassification error rates were applied. The first equation used the
misclassification error rate proportions written in terms of the adjusted count for that cell.
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So to determine the adjusted count of never smokers who tested positive for
ANA, we subtracted the error rate of smokers who misclassified themselves as never
smokers, from the unknown adjusted count, added the error rate of never smokers who
misclassified themselves as smokers and equated it all to the estimated value of never
smokers who tested positive for ANA.
Since the adjusted count was unknown and both the false negative and positive
values were also unknown, a second equation was used. The sum of the adjusted never
smokers and heavy smokers whom tested positive for ANA was the total number of cases
that tested positive for ANA. Solving for heavy-smokers, we substituted this equation
into the first and solved for the adjusted count of heavy smokers who tested positive for
ANA then solved for the adjusted count of never smokers who tested positive for ANA.
The same was done for heavy and never smokers that tested negative for ANA and the
resultant adjusted values used to determine the adjusted OR. An example below
illustrates how the adjusted OR values were created. Here never smokers are used as the
reference category.
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Table 2. Observed Data for the Comparison of Never Smokers With Heavy
Smokers in Relation to ANA Positivity and Negativity.
Heavy smokers
Never smokers
Total
X=0
X= 1
Opo — 18
ANA Positivity

Opl = 37

55

Onl = 253

309

ab
On0 = 56

ANA Negativity

cd

Now solving for heavy smokers and never smokers who test positive for ANA:
18 = a-(0.09) (a)+ (0.03) (b)

(1)

a + b = 55

(2)

b = 55 - a

18 = (0.91) (a)+ (0.03) (55-a)

b = 36.42

a = 18.58

Now solving for heavy smokers and never smokers who test negative for ANA:

56 = c - (0.09) (c) + (0.03) (d)

(3)

c + d = 309

56 = (0.91) (c) + (0.03) (309 - c)

d = 309 - c

c = 53.10

d = 255.90

(4)

The adjusted OR is then the ratio of the odds of heavy smokers who test positive for
ANA to the odds of non- smokers who test positive for ANA.

(18.58) / (53.10) / (36.42) / (255.90) = 2.46

41

CHAPTER 4
The Effects of Smoking on Antinuclear Antibody and Rheumatoid Factor Production
Publishable Paper
Susan A. Nyanzi, Jerry W. Lee, Kristian, Lindsted, Edwin H. Krick
To be submitted to the Journal of American Medical Association

42

Word Count = 4,303

The Effects of Smoking on Antinuclear Antibody and Rheumatoid Factor Production

Authors
Susan A. Nyanzi, Dr. P. H.c, Loma Linda University, School of Public Health
Jerry W. Lee, Ph.D., MA, Loma Linda University, School of Public Health
Kristian Lindsted, Loma Linda University, School of Public Health
Edwin H. Krick, M.D., Loma Linda University, School of Medicine

43

Abstract
Context'. Population and epidemiological studies suggest cigarette smoking is an
independent risk factor for initiation of Rheumatoid Arthritis (RA) possibly related to the
production of Rheumatoid Factor (RF), an autoantibody. Another collection of
autoantibodies that are now being associated with the initiation of RA and cigarette
smoking are Antinuclear Antibodies (ANA). Objectives: To determine the effects of
cigarette smoking on ANA and RF positivity in healthy blood donors. Design: Crosssectional, observational, and retrospective study in relation to smoking history. Data on
demographics, smoking history and selected risk factors were collected from selfadministered and interview-assisted questionnaires. Setting and Participants: 576
consenting volunteer blood donors recruited from the San Bernardino and Riverside
blood banks located in California, provided additional blood samples, and answered both
the general blood bank questionnaire and our questionnaire. Main Outcome Measures:
Serum titers of ANA and RF positivity. Results: A history of moderate and light lifetime
smoking was protective for ANA positivity relative to non-smoking and heavy smoking
(0/?=3.75, 95%C/= 1.28-11.05, p=0.02). Simple contrasts suggested this was due to
moderate lifetime smoking being protective for ANA positivity compared to non
smoking (0R=O.33, 95% C/=0.11-0.99, p =0.048) and heavy smoking (OR=0.17, 95%
C/=0.06-0.54, p =0.003). No associations were found between current smoking status
and ANA or RF positivity. Conclusion: Immunological changes induced by smoking or
nicotine may help explain the observed biphasic effect found with ANA positivity, in our
study population of apparently healthy blood donors.
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INTRODUCTION
Rheumatoid Arthritis (RA) is a chronic, systemic inflammatory autoimmune disorder of
unknown etiology1'5. In the United States, it is the most common inflammatory disease
with a prevalence approaching approximately 1% in white Americans and 4% in some
tribes of North American Indians, such as the Pima tribe1,6'8. Although the etiology of
RA is not fully understood, previous studies implicate both genetic and environmental
factors 2,3,5,9-11 , with genetic factors primarily playing a role in the progression of the
disease rather than in its initiation 10,12. Several environmental factors have been
associated with the initiation of RA. These include infectious agents: viral and bacterial
1,7, 13

and lifestyle factors such as smoking 6, 14-18
In the past fifteen years, epidemiological and prospective studies have shown

smokers to be at higher risk of RA development. Although the actual mechanism is
currently unclear, one possible biological mechanism is that cigarette smoking induces
the production of Rheumatoid Factor (RF). Elevated RF levels have been reported to
appear months or even years before the clinical onset of RA 16,19 and healthy subjects
with persistently elevated RF levels have been shown to be more likely to develop RA 15,
17, 20-22

. Smoking is now considered a risk factor for RA development 6, 14-18, 20-25
Another set of autoantibodies that are causing interest relative to the development

of RA by way of cigarette smoking are antinuclear antibodies (ANA); yet, studies of
ANA and smoking are limited. The two studies that we located assessed the relationship
in normal adults

26, 27

A study by Mathews, et al., (1973) was the first major study that evaluated this
association, where a dose response relationship between smoking status and ANA was
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identified in normal adults. Using an older population, Regius et. al., (1988) replicated
this finding however the presence of ANA was more frequent in females than in males.
Research has now suggested smoking is a risk factor for RA via RF production 6’
14-18, 20-25

. ANAs are associated with RA possibly also related to smoking

26-29

.This

research led us to investigate the effects of smoking on both ANA and RF in healthy
subjects. We were unable to find studies that looked at the effects of smoking on both RF
and ANA in healthy subjects. In the literature, relative to ANA, RF, and RA there appear
to be two main categories of studies: those studies that focused on assessing the effects of
smoking on RF and those that focused on assessing the effects of smoking on ANA. No
one to our knowledge has examined the effect of smoking on both autoantibodies in
healthy subjects.
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METHODS
Study Design
Participant Characteristics. Informational sheets about the study were used to recruit
583 volunteer blood donors, from 2 donation sites; the San Bernardino and the Riverside
blood banks. The American Association of Blood Bank (AABB) guidelines were applied
to all eligible donors. Cases missing data on the relevant the dependent variables; ANA
and RF positivity (n=6), the independent variables; smoking status (/z=8) and pack years
(>2=11) and the covariate variables; age and gender 0*=8) were eliminated from the
analysis dataset. Cases missing some of the variables, imputations were included using
other variables in the analysis dataset. For example if cases were missing on smoking
status, other variables such as age started smoking, age stopped smoking and are you
currently smoking were used to impute smoking status. In total 33 cases were removed
from the analysis dataset due to missing data. The demographics of the participants are
presented in Table 1.
An accurate estimate of the refusal rate could not be obtained due to the logistics
of data collection. The research coordinator was in the recovery cafeteria helping
participants answer the study questionnaire, while the front desk personnel informed
prospective participants about the study. Days on which the front desk personnel were
busy, prospective donors may have not been informed about the study. Even though the
blood bank keeps records on the number of donors per day, filtering out return donors
would have been difficult.
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To prevent repeat donors from participating in the study again, the informational
sheet, stressed the study was a one time event and the front desk personnel additionally
asked prospective donors whether they had participated in the study on their last visit.
Exclusion Criteria. In addition to the standard exclusion criteria (Appendix A)
used by the blood bank, participants were excluded if they had systemic rheumatic
conditions associated with ANA and RF levels. Participants who smoked cigars (n=10),
pipes (n=7), chewed snuff (n=l) or used any combination of the three (n=8) were also
eliminated from the dataset. A total of 59 cases were eliminated from the analysis
dataset, leaving a total of 523 participants.
Inclusion Criteria. Participants in the analysis dataset were volunteer blood
donors from the San Bernardino and Riverside blood bank sites who fully completed both
the standard blood bank questionnaire and the study questionnaire. Only participants
with complete information on the dependent, independent and covariate variables were
included in the analysis dataset.
Procedure
Prospective donors first registered at the registration desk where they were told
about the study. In addition to the Blood bank’s health history questionnaire, those who
agreed to be part of the study were given, a consent letter and the study questionnaire.
Volunteers that did not qualify for donation returned their consent letter and study
questionnaire to the front desk personnel.
Blood Samples
An extra tube of blood was drawn from each participant for the study. Collected
samples were spun down and the separated serum stored at minus 70°C. Once all the
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serum samples were collected, they were tested for both ANA and RF positivity. ANA
positivity was measured using the indirect fluorescent antibody test method, and RF
positivity was measured by the latex agglutination test.
Statistical Analysis
To describe the quantitative and qualitative relationships between the exposure
variable, and the outcome variables, chi-squared tests were used for the univariate
analyzes, with exact tests for significance 30 showing the level of significance. In
instances where the exact test could not be used the Monte Carlo test of significance was
employed. To test the multivariate models, binary logistic regression models that
controlled for potential confounders were used. All analyzes were performed using SPSS
version 10.0.
Smoking Status. Never smoker and current smoker status were coded using the
following two questions “Have you ever smoked?" and “Are you still smoking?"
Participants, who answered no to both or no to the first and missed the second question
were coded as never smokers and those who answered yes to both were coded as current
smokers.
Ex-smoker status was coded using four questions. The two above questions were
used first. If participants answered yes to the first and no to the second or if the response
to the second question was missing, participants were coded as ex-smokers. If
participants were missing data for both questions, two additional questions were used to
assess their smoking status; “At what age did you start smoking?" and “At what age did
you stop smoking?"
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Pack Years. Seven questions were used that asked participants the approximate
number of packs per day they typically smoked in seven periods of their lifetime, where
the first period was a year in length and the last nineteen years. For each period
participants were asked to estimate the approximate number of packs smoked per day.
To obtain an estimate of the packs smoked in each period, the number of years in each
period was multiplied by the reported packs smoked per day in that period. Summing the
estimates across all seven periods, gave us the pack years variable. For cases that did not
indicate a number of pack years smoked in a period but who had indicated packs smoked
for some other period or periods, we assumed they had not smoked in that period and
coded them as zero.
For participants who smoked for more than sixty years, an extra term, the estimate
of packs smoked over sixty, was added to the pack year equation. This estimate was the
product of the years smoked over sixty with the reported number of packs per day
smoked in that period.
The pack years variable was strongly positively skewed, in that a large percentage
of our subjects were never smokers, because of this, pack years was categorized into a
four level variable and that categorization used in most of our analyses.
Antinuclear Antibodies and Rheumatoid Factor. The outcome variables, the
presumed effect, were ANA and RF positivity. For ANA, titers less than 1:40 were
considered negative and those 1:40 and above were considered positive. To test for RF
positivity, titers less than 1:2 were considered negative and those 1:2 and above were
considered positive. For both ANA and RF this combining of titers was done because
insufficient positive cases were detected at higher titers.
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Potential Confounders
Both age and gender are associated with elevated ANA and RF 2, 26, 27 , so both
were treated as covariates in our models.
Confounders associated with RA development; race 5’9, estrogen and
progesterone (natural or artificial) variations

17,23,31-36

, alcohol consumption 37and

physical activity 38, were examined in relation to ANA and RF positivity. Variables that
showed significant relationships were added to our logistic regression models and
controlled for statistically.
Sensitivity Analysis
Smoking history was self-reported, so its validity even with anonymity becomes
questionable. Smokers wanting to fit in with the current social norm of not smoking
could have under-estimated the actual amount they smoked or misclassified themselves.
Smokers could have categorized themselves as never smokers and never smokers
misclassified themselves as smokers 39. To account for this, an analysis of the effects of
misclassification was performed. Based on Patrick et al’s meta-analysis” of 23 studies
with similar populations (general population) and study designs (observational) the
median false positive (3.3%) and the median false negative (9.4%) error rates were
calculated. Median values were used to reduce the impact of a few extreme cases. We
derived our error rates from a review of earlier studies that was itself published about 10
years ago so the estimated error rates may not be reflective of current smoking rates.
Nevertheless, the estimations represented the best available values that could be used in
the sensitivity analysis.
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To obtain estimates of what the odds ratio would have been had there been no
misclassification we had to work backwards from our data and from these estimated error
rates to estimate what the true counts of individuals in each cell of our crosstabulation
table. For example, to estimate the true count for heavy smokers who tested positive for
ANA (Th) we used the following data: the false positive rate (FPr), the false negative rate
(FNr), the observed count of heavy smokers testing positive for ANA (Oh), and the
observed total count of heavy smokers and never smokers who tested positive for ANA
(Ot). We had to estimate the count of heavy smokers who were false positives (FPH), the
count of never smokers who were false negatives (FNn) and the true count of never
smokers who tested positive for ANA (Tn). Then the following equations were derived:
FNn = FNr * Th

(1)

FPH =FPr * Tn

(2)

Tn = Ot - Th

(3)

Oh = Th - FNn + FPh

(4)

And from equations 1 and 2
OH = TH-FNr*TH + FPr * Tn

(5)

Since equations 3 and 5 represent two equations with two unknowns, it was possible to
solve for the two unknowns.
The estimates of the actual counts for the other cells necessary to calculate odds
ratios were determined in a similar manner. The assumption was made that there were no
errors in the qualitative testing of ANA.
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RESULTS
Age in Relation to ANA and RF Positivity
Although age was a covariate, we also examined it in relation to ANA and RF
status.
Univariate analysis showed a significant association of age with testing positive for ANA
[X2(2, #=304) = 10.32, p =. 006] and for RF [%2(2, N=304) = 8.22, p =. 016] for males.
However, the same associations were not found for females for either ANA [x(2.
#=219) = 0.06, p =. 973] or RF [%2(2, At219) = 0.025, p =. 987] (table 2).
To assess, whether gender had an effect on the association of age with ANA or
RF we looked for interactions, and but found none statistically significant.
Differences in ANA and RF Positivity in Smoking Status
Univariate analysis showed no significant differences in ANA [%2(2, A=523) =
3.199, p =. 209] or RF positivity [%2(2,7V=523) = 0.343, p =. 864] among current
smokers, ex-smokers and never smokers (table 3).
Multivariate analysis again showed that never smokers were not significantly
different from ex-smokers ((9/?=1.094, 95% C7=0.63 - 1.92, p=0.153) or current smokers
(OR=0A3, 95% C7=0.13 - 1.45,/?=0.173) with respect to testing positive for ANA. The
same was true for RF (0/?=1.12, 95% C7=0.45-2.81,/?=0.808 and OR=\A6, 95%
C7=0.39-5.41, /?=0.568, respectively). However, one-year increase in age, increased the
odds of ANA positivity by 3 % (O/?=1.03, 95% C/=1.01 - 1.05, p=0.007). We also
found that the association between smoking status and ANA and RF was not significantly
different for males and females.
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Pack Years and ANA or RF Positivity
Univariate analyzes of the demographic variables, with pack years divided into
four levels are shown in table 4. Variables that showed significant association with pack
years were added to the binary logistic models.
Pack years was significantly associated with ANA positivity [%2(3, N=523) =
13.662, p =. 003] but not with RF positivity [%2(3, N=523) = 4.013, p =. 262] (table 5).
Initial analysis showed that there was a quadratic relationship between increased pack
years and increased ANA positivity (OR=2.61, 95% C7=1.32 - 5.39, p=0.006). When
gender and the linear and quadratic trends in age were controlled for, simple contrasts
suggested that moderate smoking was protective for ANA positivity relative to never
smokers and heavy smokers. Further examination of the odds ratio in the four categories
of pack years, with a polynomial contrast additionally showed moderate smoking and
light smoking to be protective for ANA positivity compared to never smokers and heavy
smokers (table 6). We also found that the associations between pack years and ANA or
pack years and RF were not significantly different for males and females.
Overall, we were unable to show any linear or quadratic associations between RF
positivity and smoking status and between ANA positivity and smoking status. We were
able to show a non-linear relationship between ANA positivity and pack years, from
which moderate smoking was protective for ANA positivity whereas heavy smoking was
a risk factor for ANA positivity. Additionally we wanted to know whether smoking
increased the joint probability of ANA and RF positivity, however, because we had too
few cases of individuals that tested positive for both ANA and RF, we were unable to test
this hypothesis.
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Sensitivity Analysis
Table 7 compares the observed OR with the OR adjusted for the degree of
probable group misclassification for the four different levels of smoking relative to ANA
positivity. The same trend found in the unadjusted odds ratio was present. The adjusted
OR for moderate smoking, smoking between 7 to 27.5 pack years, was even more
protective for ANA positivity, compared to light and heavy smoking while heavy
smoking, smoking more than 27.5 pack years, was a risk factor for ANA positivity
compared to never smokers.
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COMMENTS
In this study, we examined the relationship of smoking with ANA and RF
positivity in apparently healthy blood donors from the San Bernardino and Riverside
blood banks. The approach used here differed from previous studies as we assessed both
linear and quadratic effects of smoking on both ANA and RF in healthy subjects. To
determine whether differences in ANA or RF positivity occurred in current smokers, ex
smokers and never smokers, we looked at smoking exposure first with regard to current
smoking status then with regard to lifetime exposure.
Examining the relationship of age and gender with ANA and RF, we found that as
males get older, they are more likely to test positive for ANA and RF. No comparable
associations were statistically significant for females. Although Regius et al., 1988,
found the same relationship in females, we found it in males.
We were unable to detect significant differences in testing positive for both ANA
and RF among current, former, and never smokers. Mathew et al., 1973, was able to
show associations of both ANA and RF with smoking status possibly because of a much
larger sample size compared to our study.
However, with regard to lifetime exposure a nonlinear relationship was found
between smoking and testing positive for ANA. Moderate smokers were 17% less likely
to test positive for ANA compared to never-smokers and never and light smokers were
less likely to be positive for ANA than heavy smokers though the differences did not
quite reach conventional level of significance. Nevertheless, there was a significant
nonlinear quadratic trend such that moderate and light smokers were less likely to be
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positive for ANA than heavy and non-smokers. No significant associations were found
between smoking and RF.
In contrast to these results, previous studies have shown smokers to be more
likely to test positive for RF than former and never smokers

16, 22,40-42

. The association

was strong enough that smoking is now considered a risk factor for RA via the elevation
of RF 6, 17, 18, 22,24, 25,41,43,44 . With documented increases in RF levels before the clinical
symptoms of RA

16,40, 42

, some studies have additionally gone on to show that symptom

free participants with stable increases in RF have a markedly increased incidence of RA
development 22, 40, 45 . Moreover, patients with RA, who smoke have been found to have
elevated RF, bone erosions and rheumatoid nodules compared to RA patients who do not
smoke

15,20, 46

. On the other hand Hazes et. al (1990) found smoking to be protective for

RA in patients with RA.
Our results do not replicate the majority of studies regarding association of RF
with smoking. In symptom free participants, we were unable to detect any linear or
quadratic effects between pack years and RF. A possible reason could have been the
relatively small number of smokers (n=53) in our sample. Of the studies that showed an
association between smoking and RF, all had larger numbers of smokers (from 63 to
1,682) and larger numbers of smokers who tested positive for RF (28 to 81) compared to
our study (n=12).
Other possible reasons could have been (i) the different titration levels used
among different studies to define positivity and (ii) the definition of smoking. Some
studies defined cigar and pipe smokers

16, 42

as smokers and included them in the analysis

dataset. In our study, cigar and pipe smokers were excluded from the analysis dataset.
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We only looked at cigarette smokers. Based on our results, another possibility could be
that ANA complexes are more susceptible to smoking or nicotine exposure than RF
complexes and the association between the two is, thus, more easily detected.
Regarding the relationship between smoking and ANA, our study was different
from the current literature in two major ways. We defined smoking exposure as pack
years, which allowed us to look at total exposure to smoking in a participant’s lifetime
and we also considered whether the type of relationship present might be non-linear. To
our knowledge no other study has done both.
In Caspi et al., (2001) Mathews et al., (1973) Regius et al., (1988) and SaudanKister et al., (1996) only linear relationships have been documented. Again sample size
was a factor in detecting a linear association. However, tests of non-linear relationships
such as quadratic associations have not been reported. From our data, a quadratic
relationship was found between smoking and ANA positivity suggesting that smoking
possibly has a biphasic effect on ANA positivity.
Biphasic effects of smoking on biological systems are not new. In experimental
preparations, nicotine in low doses causes ganglionic stimulation but in high doses
ganglionic blockade results 47. Cigarette smokers also report that usually the first
cigarette of the day produces arousal while during stressful situations, smoking produces
relaxation

47-49

. Nicotine, the major addictive element of tobacco, is the driving focus

behind this observed biphasic effect. An effect that could be a consequence of nicotine
binding to a subset of receptors called the a3, in the nicotinic acetylcholine receptor
(nAChR) family 47-50
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Nicotinic acetylcholine receptors are abundant in the centers of the brain that
mediate reward behaviors and are either activated or inactivated by acute and chronic
levels of nicotine exposure 47-50 . Acute nicotine exposure levels are generally associated
with a specific conformational change that are associated with receptor activation and
chronic nicotine exposure levels are associated with an other specific conformational
change associated with receptor inactivation 49,51
In depression 49,52 , neurodegenerative disorders such as Parkinson’s disease and
senile dementia Alzheimer 48,49,52,53 chronic nicotine exposure is beneficial apparently
because nicotine causes a greater release of dopamine and at the same time slows down
its breakdown.
In Attention-Deficit Hyperactivity Disorder (ADHD)52 and schizophrenia 49,52
activation of nAChRs, by nicotine exposure, is thought to account for improvements in
symptomatologies such as impaired attentiveness, increased impulsivity and anhedonia
(diminished interest or pleasure) and avolition (lack of motivation).
In studies more closely related to immunological affects there are several studies
that show the protective effects of smoking. These include ulcerative colitis 46,51,53-55
Sarcoidosis

53,56

, Inflammatory acne 46, 53, 55, 57 , and Osteoarthritis (OA) 46, 58, 59

Assessing our results, smoking, possibly nicotine, has a biphasic effect on ANA
positivity. There is now considerable evidence that ANA complexes are a part of a
healthy immune system, where they help in the clearance of immune complexes by
forming large sized complexes that are easily removed by the body’s defense system.
ANA complexes become pathogenic when they activate inflammatory responses via the
complement cascade. In neurodegenerative diseases chronic nicotine exposure has been
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found to result in a3 nAChR inactivation 47-50 . Conversely in one inflammatory disease,
ulcerative colitis, acute nicotine exposure may result in a3 nAChR activation.
Applying a similar concept acute nicotine exposure or, moderate smoking may
cause surface receptors on ANA complexes to under go conformational changes that
would enhance the formation of large sized complexes. These large sized complexes
would in turn aid the body’s defense system in the removal of detrimental immune
complexes, making smoking or nicotine protective for testing positive for ANA. On the
other hand, chronic nicotine exposure or heavy smoking may result in conformational
changes that inactivate the ANA complexes. Inactivation of the complexes would cause
a build up of detrimental immune complexes which would trigger the production of more
ANA complexes. Exposure to high levels of nicotine would inactivate the ANA
complexes and set up a vicious cycle. Build up of ANA complexes then trigger the
activation of complement which releases a cascade of inflammatory responses.
Another possibility for the curvilinear effect could simply be that participants who
choose to smoke moderately may be different from never smokers and from heavy
smokers on some unmeasured confounding variable and this confounding variable might
account for the differences seen.
Among the limitations of this report, measurement bias may have been possible.
Smoking history was self-reported from a self-administered questionnaire. However, the
research in this area suggests that self-reporting of adult smokers are apt to be veridical in
settings not involving an intervention trail

39,60

and the questionnaires were anonymous

providing no reason for individuals to misreport their smoking habits.
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Nevertheless, we carried out a sensitivity analysis to test what might happen if our
respondent self-reports were non-veridical and lead to misclassification of their smoking
status. The adjusted OR values showed a stronger effect compared to the observed OR
values, suggesting that the protective effects of cigarette smoking might be even stronger
with less misclassification.
In conclusion, we have demonstrated the biphasic effects of smoking on ANA
positivity and have proposed a possible mechanism. The effects of smoking are complex.
in contrast to its many adverse effects smoking is now being shown to have beneficial
effects in neurodegenerative disorders such as; Parkinson’s, Alzheimer’s, depression,
ADHD and schizophrenia and in some inflammatory disorders such as; ulcerative colitis,
sarcoidosis, inflammatory acne, OA and RA.
Although the detrimental effects of smoking on various organs have been
extensively studied, the protective effects have received little attention. In mentioning
these beneficial effects, we are not advocating smoking but rather attempting to reach a
better understanding of all the effects of cigarette smoking on human diseases.
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Tablel. Participant Characteristics
Participants
N

%

Male

304

58.13

Female

219

41.87

Black/African American

20

3.82

Caucasian

427

81.64

Hispanic / Latino

73

13.96

Native American

11

2.10

Asian or Pacific

12

2.29

Other

6

1.15

Demographics
Sex

Ethnicity*

♦Percentages for ethnicity add up to more than 100 because individuals
were allowed to choose more than one ethnicity
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Tablel. Participant Characteristics Cont...
Participants
N

%

Below high school

15

2.87

High school diploma

181

34.61

Trade school diploma

49

9.37

Associate degree

94

17.97

Bachelors degree

113

21.61

Masters degree

54

10.33

Doctoral degree

17

3.25

Never smokers

290

55.45

Ex-smokers

180

34.42

Current smokers

53

10.13

Mean

SD

48.3

14.1

Demographics
Education

Smoking status

Age at questionnaire submission

71

Table 2. Crosstabs of Age and Gender for Testing Positive for ANA and RF
Males
Females
Negative Positive

N Negative Positive

N

21-40 age category

95.16% 4.84%

62

86.90% 13.10%

84

41-60 age category

89.41% 10.59% 170 85.71% 14.29%

98

61 and older age category

77.78% 22.22%

72

86.49% 13.51%

37

21-40 age category

100.00%

62

95.24%

4.76%

84

41-60 age category

96.47% 3.53%

170

94.90%

5.10%

98

61 and older age category

90.28% 9.72%

72

94.59%

5.41%

37

Categories of age
ANA status

RF status
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Table 3. Association of ANA and RF Status With Smoking Status
N
Negative
Positive
Smoking status
ANA status
Never smokers

87.24%

12.76%

290

Ex-smokers

85.00%

15.00%

180

Current smokers

94.34%

5.66%

53

Never smokers

95.86%

4.14%

290

Ex-smokers

95.00%

5.00%

180

Current smokers

94.34%

5.66%

53

RF status

73

Table 4. Association of Demographic Variables With Pack Years
Pack years
Never
Less than
Between Greater than
smokers

7

7-27.5

27.5

Variables

(N = 290)

(N = 79)

(N = 80)

(N = 74)

Mean age

46.14

44.01

51.99

56.81

Gender

Sig.

0.007
0.000

Males

49.01%

13.16%

18.09%

19.74%

Females

64.38%

17.81%

11.42%

6.39%

African-American

80.00%

10.00%

5.00%

5.00%

0.135 i

Caucasian

60.42%

19.79%

13.54%

6.25%

0.053

i

Hispanic

58.90%

21.92%

13.70%

5.48%

0.058

i

Native American

55.86%

14.65%

15.23%

14.26%

0.222

i

Asian or Pacific

75.00%

8.33%

16.67%

0.442

i

Other

50.00%

16.67%

16.67%

Ethnicity

i

16.67%

1.000 i

Because people could choose more than one ethnicity, this significance test is the contrast of people who
choose this ethnic group versus those who did not choose this group.
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Table 4. Association of Demographic Variables With Pack Years Cont...
Pack years
Never
Less than
Between Greater than
smokers

7

7-27.5

27.5

(N = 79)

(N = 80)

(N = 74)

Sig.

(N =
Variables

290)

0.153

Education
None

2.76%

3.80%

2.50%

2.70%

High school

33.45%

32.91%

38.75%

36.49%

Trade school

7.24%

13.92%

12.50%

9.46%

Associate degree

15.86%

22.78%

21.25%

17.57%

Bachelors degree

23.79%

16.46%

13.75%

27.03%

Masters degree

13.79%

8.86%

7.50%

1.35%

Doctoral degree

3.10%

1.27%

3.75%

5.41%

75

Table 5. ANA and RF Status With Pack Years
Pack years categories

Negative

Positive

N

Never smokers

87.24%

12.76%

290

Up to 7 pack years

89.87%

10.13%

79

7 to 27.5 pack years

95.00%

5.00%

80

More than 27.5 pack years

75.68%

24.32%

74

Never smokers

95.86%

4.14%

290

Up to 7 pack years

96.20%

3.80%

79

7 to 27.5 pack years

91.25%

8.75%

80

More than 27.5 pack years

97.30%

2.70%

74

ANA status

RF status

76

Table 6. Logistic Regression of ANA and RF Status on Pack Years Controlling for
Gender, as Well as Linear and Quadratic Effects of Age
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

ANA (ANA-negative=456, ANA-positive=67 N=523)
Never smokers=290 *

1.000

Up to 7 pack years=79

0.781

0.343

1.777

0.556

7 to 27.5 pack years=80

0.337

0.115

0.989

0.048

More than 27.5 pack years=74

1.942

0.982

3.844

0.057

Current age

1.025

1.005

1.045

0.014

Gender

1.426

0.818

2.487

0.211

Current age squared

1.000

0.999

1.001

0.400

Constant

0.020

77

0.000

Table 6. Logistic Regression of ANA and RF Status on Pack Years Controlling for
Gender, as Well as Linear and Quadratic Effects of Age Cont...
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

RF (RF-negative=499, RF-positive=24 N=523)
Never smokers=290 *

1.000

Up to 7 pack years=79

0.851

0.227

3.191

0.810

7 to 27.5 pack years=80

2.203

0.806

6.018

0.123

More than 27.5 pack years=74

0.575

0.119

2.772

0.490

Current age

1.021

0.993

1.050

0.149

Gender

1.348

0.565

3.212

0.501

Current age squared

1.001

1.000

1.003

0.128

Constant

0.008

♦Never smokers are the reference category

78

0.000

Table 7. Odds Ratios for the Relationship of ANA Status to Pack
Years Smoked. Includes Odds Ratios Adjusted for Possible
Misclassification of Smoking Status
Observed
Adjusted
Never smokers*
Light smokers
(0-7 pack years)

1.00

1.00

0.77

0.74

Moderate smokers
(7 to 27.5 pack years)

0.36

0.28

Heavy smokers
(>27.5 pack years)

2.2

2.46

*Never smokers are the reference category
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CHAPTER 5
OTHER FINDINGS
A. Smoking Status
Multivariate analyzes showed never smokers were not significantly different from
ex and current smokers in respect to testing positive for ANA and RF in a linear
relationship (See Table 1). However, age was associated with ANA positivity in that
older participants were more likely to test positive for ANA.
Table 1. Logistic Regression of RF and ANA Status in Relation to Smoking Status
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=456, ANA-positive=6, N=523)
Smoking status
Non-smoker* (n=290)

1.000

Ex-smoker (n=180)

1.094

0.625

1.916

0.753

Current smoker (n=53)

0.428

0.127

1.451

0.173

Current age

1.028

1.008

1.048

0.007

Gender

1.380

0.803

2.372

0.244

Constant

0.019

80

0.338

0.000

Table 1. Logistic Regression of RF and ANA Status in Relation to Smoking Status
Cont...
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

Dependent: RF(RF-negative=499, RF-positive=24, N=523)
Smoking status
0.846

Non-smoker* (n=290)
Ex-smoker (n=180)

1.121

0.447

2.812

0.808

Current smoker (n=53)

1.464

0.396

5.410

0.568

Current age

1.025

0.994

1.058

0.114

Gender

1.382

0.588

3.251

0.458

Constant

0.009

0.000

* Nonsmokers as reference group

B. Qualitative Aspects of Smoking in Relation to ANA and RF Positivity
Tar and nicotine levels did not significantly influence ANA or RF positivity in
our study population.
C. Exposure to Second Hand Smoke
1. Past Second Hand Smoke
Neither linear nor non-linear relationships were detected between past
second hand smoke exposure and ANA or RF positivity. However, older participants
were more likely to test positive for ANA.
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2. Current Second Hand Smoke for Ex-Smokers and Never Smokers
Current second hand smoke was assessed in ex and never smokers only,
because second hand smoke in current smokers would be heavily confounded with their
own smoking. Due to their smoking habit and their social circle, assuming that most of
their friends smoke, current smokers would have higher than normal levels of second
hand exposure.
To test for quadratic relationships, squared terms for current second hand smoke
and age were included in our models, and no significant associations were found.
However, older participants were more likely to test positive for ANA (see Table 2).
To assess for non-linear relationships, linear, quadratic and tertiary models were
contrasted and still no associations were found (see Table 3).
3. Dichotomous Second Hand Smoke for Ex-Smokers and Never Smokers
Second hand smoke was then categorized as a dichotomous variable;
exposed or non-exposed. Even as a dichotomous variable, a significant linear
relationship between ANA or RF positivity was not detected (see Table 4). Again,
current age increased the odds of testing positive for ANA.
4. Dichotomous Second Hand Smoke for Never Smokers
Looking at never smokers only, with second hand smoke defined as
exposed and non-exposed, we were unable to detect a linear relationship between second
hand smoke and ANA and RF positivity (see Table 5).

82

Table 2. Logistic Regression of RF and ANA Status With the Squared Terms of
Current Second Hand Smoke and Age
95.0% CL
Covariates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=295, ANA-positive=43, N=338)
Current second hand smoke

1.112

0.766

1.612

0.577

Squared current second hand smoke

1.131

0.901

1.419

0.290

Current age

1.029

1.005

1.054

0.019

Squared current age

1.001

1.000

1.002

0.087

Gender

1.161

0.572

2.353

0.680

Constant

0.017

0.000

Dependent: RF (RF-negative=320, RF-positive=18, N=338)
Current second hand smoke

1.057

0.614

1.820

0.841

Squared current second hand smoke

1.175

0.873

1.582

0.287

Current age

1.026

0.991

1.062

0.151

Squared current age

1.001

0.999

1.003

0.250

Gender

1.077

0.376

3.084

0.890

Constant

0.009
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0.001

Table 3. Logistic Regression of ANA and RF Status in Relation to Current Second
Hand Smoke for Ex-Smokers and Never Smokers Using Polynomial Contrast
95.0% C.L
Co variates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=294, ANA-positive=43, N=337)
Current second hand smoke
0.412

Overall association
Linear association

1.846

0.867

3.933

0.112

Quadratic association

1.469

0.707

3.051

0.303

Tertiary association

1.116

0.547

2.275

0.763

Current age

1.034

1.008

1.061

0.009

Gender

1.227

0.609

2.470

0.567

Constant

0.022

0.000

Dependent: RF (RF-negative=320, RF-positive=18, N=338)
Current second hand smoke
0.489

Overall association
Linear association

2.001

0.717

5.589

0.185

Quadratic association

1.797

0.627

5.155

0.276

Tertiary association

0.940

0.319

2.773

0.911

Current age

1.032

0.994

1.071

0.097

Gender

1.120

0.398

3.150

0.829

Constant

0.011
84

0.001

Table 4. Logistic Regression of ANA and RF Status in Relation to Exposed and NonExposed for Second Hand Smoke for Ex-Smokers and Never Smokers
95.0% C.I.
Odds ratio

Covariates

Lower

Upper

Sig.

Dependent: ANA (ANA-negative =295, ANA-positive =43, N=338)
Dichotomous second hand smoke

1.198

0.606

2.365

0.604

Current age

1.033

1.007

1.060

0.012

Gender

1.279

0.640

2.556

0.486

Constant

0.018

0.000

Dependent: RF (RF-negative=369, RF-positive=21, N=390)
Dichotomous second hand smoke

1.052

0.412

2.688

0.916

Current age

1.026

0.992

1.062

0.137

Gender

1.072

0.418

2.751

0.884

Constant

0.013

85

0.002

Table 5. Logistic Regression of ANA and RF Status in Relation to Exposed and NonExposed for Second Hand Smoke Exposure for Never Smokers
95.0% C.I.
Odds ratio

Covariates

Lower

Upper

Sig.

Dependent: ANA (ANA-negative =145, ANA-positive =16, N=161)
Dichotomous second hand smoke

1.236

0.414

3.685

0.704

Current age

0.991

0.950

1.032

0.651

Gender

1.363

0.477

3.898

0.563

Constant

0.094

0.103

Dependent: RF (RF-negative=151, RF-positive=10, N=161)
Dichotomous second hand smoke

0.765

0.194

3.020

0.702

Current age

1.024

0.974

1.077

0.352

Gender

1.039

0.283

3.809

0.954

Constant

0.023

86

0.034

5. Interaction of Dichotomous Second Hand Smoke Exposure With Age for
Never Smokers
For never smokers, when second hand smoke was combined with centered
age, the interaction term, had a protective effect on ANA positivity as shown in Table 6.
The type of interaction is shown in Figure 3. Second had smoke seems to protect against
ANA positivity and this effect is stronger in older age groups.
Table 6. Logistic Regression of ANA and RF Status With the Interaction of Dichotomous
Second Hand Smoke With Age for Never Smokers
95.0% C.I.
Odds ratio

Covariates

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=145, ANA-positive=16, N=161)
Dichotomous second hand smoke

0.833

0.209

3.321

0.795

Current age

1.038

0.975

1.105

0.249

Interaction: second hand smoke*centered
age

0.908

0.828

0.996

0.042

Gender

0.974

0.321

2.954

0.962

Constant

0.015

0.025

Dependent: RF (RF-negative =151 RF-positive =10, N=161)
Dichotomous second hand smoke

0.613

0.100

3.750

0.597

Current age

1.073

0.995

1.156

0.066

Gender

0.891
0.699

0.790
0.177

1.005
2.762

0.059
0.610

Constant

0.003

Interaction: second hand smoke*centered
age

87

0.013

Figure 1. Interaction of Dichotomous Second Hand Smoke Exposure with Centered Age for
Non- Smokers in Predicting ANA Positivity
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D. Total Years Smoke Exposure
1. Total Years Smoked for All
The linear association of total years smoked did not influence ANA or RF
positivity. However, current age did increase the risk of testing positive for ANA by one
(see Table 7).
Table 7. Logistic Regression of the Linear Association of ANA and RF Status in
Relation to Total Years Smoked for All
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=452, ANA-positive=67 , N=519)
Years smoked

1.009

0.990

1.028

0.344

Current age

1.026

1.006

1.047

0.012

Gender

1.382

0.808

2.365

0.237

Constant

0.023

0.000

Dependent: RF (RF-negative =495, RF-positive =24, N=519)
Years smoked

1.019

0.991

1.047

0.186

Current age

1.018

0.986

1.052

0.271

Gender

1.445

0.616

3.391

0.397

Constant

0.009

89

0.000

The quadratic association in the form of a squared term in the linear model of
total years smoked did not influence ANA or RF positivity. However, current age still
had an effect on ANA positivity (see Table 8).
Table 8. Logistic Regression of ANA and RF Status With the Squared Terms in
Relation to Total Years Smoked for All
95.0% C.I.
Co variates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=452, ANA-positive=67, N=519)
Squared years smoked

1.000

0.999

1.001

0.936

Years smoked

1.008

0.976

1.041

0.627

Current age

1.026

1.006

1.047

0.013

Gender

1.380

0.804

2.366

0.242

Constant

0.023

0.000

Dependent: RF (RF-negative =495 RF-positive =24, N=519)
Squared years smoked

1.000

0.999

1.002

0.889

Years smoked

1.016

0.968

1.067

0.524

Current age

1.018

0.986

1.052

0.276

Gender

1.436

0.609

3.386

0.409

Constant

0.010

90

0.000

2. Squared Years Smoked and Squared Age for All in Relation to ANA.
With the squared term of years smoked and current age for ANA, years
smoked was still not associated with ANA. However, current age was still associated
with ANA (see Table 9).
Table 9. Logistic Regression of ANA Status With Squared Years Smoked and
Squared Age for All
95.0% C.I.
Co variates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=452, ANA-positive=67, N=519)
Squared years smoked

1.000

0.999

1.001

0.970

Years smoked

1.009

0.977

1.042

0.584

Squared current age

1.000

0.999

1.001

0.492

Current age

1.025

1.005

1.046

0.015

Gender

1.369

0.797

2.353

0.256

Constant

0.023

0.000

Using polynomial contrast, the linear and quadratic terms of years smoked were
not associated with ANA. However, current age was still associated with ANA (see
Table 10).
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Table 10. Logistic Regression of ANA and RF Status With the Linear and
Quadratic Terms for Categorical Years Smoked for All
95.0% C.I.
Co variates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=452, ANA-positive=67, N=519)
0.689

Overall association
Linear association

1.208

0.668

2.187

0.532

Quadratic association

1.108

0.591

2.076

0.750

Tertiary association

0.675

0.341

1.337

0.260

Current age

1.027

1.006

1.048

0.011

Gender

1.344

0.784

2.304

0.282

Constant

0.025

0.000

Dependent: RF (RF-negative=495, RF-positive=24, N=519)
0.381

Overall association
Linear association

1.794

0.761

4.227

0.181

Quadratic association

2.097

0.734

5.985

0.167

Tertiary association

0.913

0.263

3.167

0.886

Current age

1.018

0.985

1.051

0.291

Gender

1.386

0.589

3.264

0.454

Constant

0.012

92

0.000

3. Total Years Smoked for Ex-Smokers
Focusing on just Ex-smokers, total years of smoke exposure increased the
likelihood of testing positive for ANA positivity and but not for RF positivity (see Table
11).
Table 11. Logistic Regression of ANA and RF Status in Relation to Total Years
Smoked for Ex-Smokers
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=152, ANA-positive=27, N=179)
Years smoked

1.045

1.007

1.084

0.021

Current age

1.040

0.996

1.087

0.077

Gender

1.765

0.655

4.758

0.261

Constant

0.004

0.000

Dependent: RF (RF-negative=170, RF-positive=9, N=179)
Years smoked

1.038

0.980

1.100

0.200

Current age

1.016

0.949

1.087

0.647

Gender

0.951

0.176

5.142

0.953

Constant

0.011
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0.049

4. Total Years Smoked for Current Smokers
Focusing on just current smokers, no associations were found with ANA
or RF positivity (see Table 12).
Table 12. Logistic Regression of ANA and RF Status in Relation to Years Smoked
for Current Smokers
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative= 47, ANA-positive= 3, N=50)
Current smokers

0.986

0.800

1.217

0.898

Current age

0.987

0.778

1.252

0.914

8627.480

0.000

8.847E+48

0.864

Gender
Constant

0.856

0.000

Dependent: RF (RF-negative=47, RF-positive=3, N=50)
Current smokers

1.033

0.878

1.215

0.698

Current age

0.969

0.788

1.191

0.764

Gender

0.492

0.036

6.746

0.595

Constant

0.288

94

0.758

5. Total Years Smoked for Ex-Smokers and Current Smokers
Also when we looked at ex-smokers and current smokers together, no
associations were found with ANA or RF positivity (see Table 13).
Table 13. Logistic Regression of ANA and RF Status in Relation to Total Years
Smoked for Ex-Smokers and Current Smokers
95.0% C.I.
Covariates

Odds ratio

Lower

Upper

Sig.

Dependent: ANA (ANA-negative=199, ANA-positive=30, N=229)
Years smoked

1.014

0.985

1.044

0.339

Current age

1.047

1.010

1.086

0.012

Gender

1.782

0.753

4.221

0.189

Constant

0.004

0.000

Dependent: RF (RF-negative=217, RF-positive=12, N=229)
Years smoked

1.030

0.986

1.077

0.184

Current age

1.009

0.956

1.065

0.749

Gender

0.756

0.187

3.060

0.695

Constant

0.026

95

0.043

CHAPTER 6
CONCLUSIONS
In this study, we examined the relationship between smoking and testing positive
for ANA and RF in apparently healthy blood donors from the San Bernardino and
Riverside blood banks. The approach used differed from previous research because we
assessed linear and non-linear effects of smoking on ANA and RF in apparently healthy
subjects.
A. Summary
Examining the relationship of age and gender with ANA and RF, we found that as
males get older, they are more likely to test positive for ANA and RF. No comparable
associations were statistically significant for females. Although Regius et al., 1988,
found the same relationship in females, we found it in males.
To answer our first question, no significant differences among current smokers,
ex-smokers and never smokers in relation to ANA and RF positivity were detected.
Patterns in missing data lowered the portion of usable data of smokers in our sample.
Because of this, the small number of smokers was probably not enough to detect the
associations between smoking status & RF & ANA.
To answer our second question of whether lifetime exposure to cigarette smoke
was related to ANA or RF positivity, we looked at smoking exposure as a continuous
variable called pack years. Here a non-linear relationship was found between smoking
and testing positive for ANA. Moderate smokers, smoking between 7 to 27.5 pack years,
were 17% less likely to test ANA, compared to light and heavy smoking, while heavy
smokers (smoking more than 27.5 pack years) were more likely to test positive for ANA
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compared to never smokers. Additionally age alone increased the risk of testing positive
for ANA in heavy smokers. No significant associations were found between smoking
and RF positivity. Further discussion of this is explained in more detail in the
publishable paper, chapter 4.
The third relationship we examined was that of nicotine and tar levels in relation
to testing positive for ANA and RF. Here we assessed the relationship in cases that had
values for nicotine and tar. No significant linear and non-linear relationships were
detected for either nicotine or tar levels. Even though we used “The Report of Tar,
Nicotine, and Carbon Monoxide Content of the Smoke of 1206 Varieties of Domestic
Cigarettes for the year 1994” (Commission, 1994), it only listed the most common
cigarette brands, therefore not all the cigarettes in our data bases were listed on the report.
Another point, some of our current smokers, smoked several brands of cigarettes at the
same time and some of ex-smokers forgot the brand of cigarettes they smoked. Because
of this unreliability in this data, the sample size we had to for analysis of nicotine and tar
exposure was probably not large enough to detect an effect.
To answer our fourth question of whether second hand smoke was related to ANA
or RF positivity, second hand smoke exposure was divided into past and current
exposure. Past second hand smoke was assessed in all participants whereas current
second hand smoke was assessed in only ex and never smokers. Nonetheless, significant
linear and quadratic associations with either RF or ANA positivity were not detected
when past and current second hand smoke exposures were defined as continuous
variables. Although age was significant in all the current second hand models, the
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interaction of age with current second hand smoke in relation to ANA or RF positivity
was not significant.
When second hand smoke was defined as a dichotomous variable; exposed and
non-exposed, and combined with centered age a weak protective effect was found with
ANA positivity. Those not exposed to second hand smoke had increased probability of
ANA positivity with age. Those exposed to second hand smoke had no such increase.
A possible reason for our null findings for the main effects could have been that the
protective effect of smoking on ANA requires time to accumulate only manifesting itself
in older adults. This was, in fact, what the interaction of age and smoking exposure
suggested.
B. Additional Findings
Significant linear and nonlinear associations were not detected for total years
smoked when everybody was included in the analysis, however, when we focused on just
ex-smokers total years exposed increased the risk of testing positive for ANA.
Combining current smokers with ex-smokers no associations were found nor were any
found with current smokers. An explanation for the increased risk for ANA positivity for
ex-smokers might be that smoke exposure produces a permanent physiological change on
the formation of ANA complexes that is irreversible. So once the detrimental complexes
are formed, they are gradually produced over time and their accumulation over the years
increases the risk of ANA positivity. Our participants could have been younger and had
not had the chance yet to accumulate changes in ANA and RF complexes.
In conclusion, our study contributes to the literature in several ways. We looked
at both linear and non-linear effects of smoking in relation to ANA and RF positivity and
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found a quadratic relationship between smoking and ANA positivity. In the literature.
only linear associations have been evaluated. Looking at qualitative aspects of cigarette
smoke, specifically nicotine and tar levels in relation to ANA and RF positivity, no
associations were found, probably due to the small number of cases in our analysis.
Even though our findings were not significant, to our knowledge this relationship has not
been assessed in the literature.
Second hand smoke, past or current, was also assessed in relation to ANA and RF
positivity, however, unreliability in the assessment of second hand smoke exposure could
have resulted in the non-significant results we found. Finally we looked at total years
smoked in relation to ANA and RF positivity and found it to increase the risk of ANA
positivity in ex-smokers.
C. Strength and Limitations
Strength of the study is that no other study has examined the linear and non-linear
effects of smoking status and lifetime smoking history, on either ANA or RF positivity in
apparently healthy subjects as well as determined whether second hand smoke had an
effect on both ANA and RF positivity. However, we did have some limitations regarding
internal and external validity.
1. Internal Validity Limitations
a. Ambiguity About Direction Of Causal Influence. This bias is an
inherent part of observational designs, so eliminating it is impossible. Causality, derived
from correlations alone between two or more variables is difficult to imply with a great
amount of certainty, because of extraneous factors. The best way to reduce it would have
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been to assess the associations we examined longitudinally. However we were unable to
do this.
b. Mono-Method Bias. The study questionnaire was administered only
once. Since we assessed smoking history by one method only, this bias could have
affected our results. Subjects could have honestly forgotten how many cigarettes they
had smoked or they have been reluctant to admit their actual usage.
Again, it would have been impossible to eliminate this bias. Possible ways we
could have reduced it would have been by the following methods. Gathering relevant
information about the subjects indirectly, besides the pen and paper method, which would
have included; performing additional one on one interviews, where the interviewer could
nudge the subject’s memory, and asking a family member or the subject themselves to
note down each cigarette they smoke, i.e. a form of dairy taking. Another possibility
could have been interviewing the subject’s co-workers and / or relatives, so as to get a
more accurate picture of their smoking history and/or habit. Since doing all of this would
be expensive and time consuming, we could not remove this bias. However, if our
methods and results are replicable, then replication could show that this bias is relatively
low.
2. External Validity Limitations
Generalizability of our results may be limited to just the study population we
used, volunteer blood donors at the San Bernardino and Riverside blood banks. Possible
reasons could be related to the selection of participants in our study, such as
representation of other ethnic populations, however small or over sampling of one ethnic
group.
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Representation of other ethnic groups, however small, could have resulted in the
results we found. Compared to other studies in this area, which were mostly done in
Scandinavian countries, our population was more ethnically diverse. Ethnic diversity in
Scandinavian countries might be limited compared to that found in the Inland Empire.
So the inclusion of other ethnic groups, however, small, could explain our results.
Secondly, over sampling of an ethnic population could have also been a
limitation.
Comparing the study’s ethnic break down to that of the Inland Empire, we had more
Caucasians in our sample and since RA is more prevalent in Caucasians, the greater
number of Caucasians in our study may have been over sampled and resulted in the
outcome we found.
D. Future Research
Even with our under-estimation of smokers in the blood donor population at the
sites we conducted the study, we partly answered our research questions and we found
some surprising findings. More studies need to be done in healthy smokers to
substantiate the biphasic effect of smoking in relation to ANA positivity. The lack of
association between smoking and RF in our study is somewhat perplexing since the
literature in this area has this finding well established. Statistically, a possible reason
could have been low power due to the small sample size we had. Biologically, a possible
reason could be, well before detrimental RF complexes are activated, smoking first
activates detrimental ANA complexes until a critical level is reached, after which
detrimental RF complexes become evident.
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E. Significance to Preventive Care
As a Preventive Care Specialist, the results of the study can be used in two major
ways. If the protective effect of moderate smoking to ANA positivity is truly present
then this information could be used to discover possible treatment therapies.
In neurodegenerative diseases such Parkinson’s, Alzheimer’s and Depression,
smoking was associated with reducing negative affects for each disorder. This
association then led to a biochemical mechanism that showed nicotine in smoke as the
culprit for the reduced symptomatologies and protective effects. Because of this nicotine
in the form of nicotine replacement therapies such as nicotine patches show promise as
future therapies in improving symptomatologies in the respective disorders.
Similarly, the components in smoking that are associated with protecting against
ANA positivity, could be revealed and used to develop treatment therapies for chronic
rheumatic disorders such as Rheumatoid Arthritis. As prevention advocates, this would
be valuable information to use and share with other health care practitioners in the early
prevention of systemic rheumatic disorders and definitely in the management of these
disorders.
The second finding of the study, that heavy smoking compared to never smoking
almost doubles the odds of testing positive for ANA, a known risk factor of RA, could be
used as an additional weapon in the fight for more smoking cessation programs. Since
we have the training to develop, implement and coordinate smoking cessation programs
this information could be incorporated into existing and new programs. In an academic
setting, this finding would support current literature that smoking is a risk factor for RA
development and additionally contribute, the specific finding, that heavy smoking
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compared to never smoking almost doubles the odds that one will test positive for a risk
factor of RA and secondly, total years smoked increases a risk factor of RA, for ex
smokers.
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Appendix A
Blood Bank's Exclusion Criteria
Blood samples that tested positive for the factors listed below were discarded.
Blood Bank's Exclusion Criteria
Variables
Hepatitis B
Surface antigen (HbsAg)
Core antibody (anti-HBc)
Hepatitis C
Virus antibody (anti-HCV)
HIV-1 antibody
Anti-HIV-1
HIV-2 antibody
Anti-HIV-2
HIV p24 antigen
HTLV-I antibody
Anti-HTLV-I
HTLV-n antibody
Anti-HTLV-n)
Serologic test for syphilis
Nucleic Acid Amplification Testing (NAT)
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Appendix C
Resources
San Bernardino blood bank used its own protocol for the blood drawing process. The
samples were then centrifuged and frozen till all the samples were collected. At the
Internal Medicine lab at the Loma Linda Medical University the frozen blood samples
were analyzed using two separate protocols. For RF, the Latex Agglutination protocol
was used and for ANA, the Florescent Antinuclear Antibody (FANA) protocol was used.
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